As
filed with the Securities and Exchange Commission on December 20, 2023
Registration
No. 333-
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
F-3
REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933
GENETIC
TECHNOLOGIES LIMITED
(Exact
name of registrant as specified in its charter)
Not
Applicable
(Translation of registrant’s name into English)
Australia
(State or other Jurisdiction
of
Incorporation or
Organization) |
|
Not
Applicable
(I.R.S. Employer
Identification No.) |
60-66
Hanover Street
Fitzroy, Victoria, 3065, Australia
Tel: 011613-9415-1135
(Address and telephone number of registrant’s principal executive offices)
Simon
Morriss
60-66
Hanover Street
Fitzroy,
Victoria, 3065, Australia
Tel:
011613-9415-1135
(Name, address and telephone number of agent for service)
Copies
of all communications, including communications sent to agent for service, should be sent to:
Darrin
M. Ocasio, Esq.
Avital
Perlman, Esq.
Sichenzia
Ross Ference Carmel LLP
1185
Avenue of the Americas, 37th Floor
New
York, NY 10038
(212)
930-9700
Approximate
date of commencement of proposed sale to the public: From time to time after the effective date of this registration
statement.
If
only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the
following box. ☐
If
any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box. ☒
If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering. ☐
If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If
this Form is a registration statement pursuant to General Instruction I.C. or a post-effective amendment thereto that shall become effective
upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box ☐
If
this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.C. filed to register additional
securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box ☐
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.
Emerging
growth company ☐
If
an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 7(a)(2)(B) of the Securities Act. ☐
The
Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective
on such date as the Commission, acting pursuant to such Section 8(a), may determine.
The
information in this prospectus may be changed. We may not sell these securities until this registration statement filed with the Securities
and Exchange Commission is declared effective. This prospectus is not an offer to sell these securities, and we are not soliciting an
offer to buy these securities in any state where the offer or sale is not permitted.
Subject
to Completion, Dated December 20, 2023
PROSPECTUS
$75,000,000
American Depositary Shares Representing Ordinary Shares
Preference Shares
Warrants
Units
Genetic
Technologies Limited
We
may offer, issue and sell from time to time up to $75,000,000 of our ordinary shares, in the form of American Depositary Shares, or ADSs,
preference shares, warrants to purchase ordinary shares, in the form of ADSs and a combination of such securities, separately or as units,
in one or more offerings. Each ADS represents 30 ordinary shares. This prospectus provides a general description of offerings of these
securities that we may undertake.
We
refer to our ADSs, ordinary shares, preference shares, warrants, and units collectively as “securities” in this prospectus.
Each
time we sell our securities pursuant to this prospectus, we will provide the specific terms of such offering in a supplement to this
prospectus. The prospectus supplement may also add, update, or change information contained in this prospectus. You should read this
prospectus, the accompanying prospectus supplement, together with the additional information described under the heading “Where
You Can More Find Information,” before you make your investment decision.
We
may, from time to time, offer to sell the securities, through public or private transactions, directly or through underwriters, agents
or dealers, on or off the Nasdaq Capital Market, at prevailing market prices or at privately negotiated prices. If any underwriters,
agents or dealers are involved in the sale of any of these securities, the applicable prospectus supplement will set forth the names
of the underwriter, agent or dealer and any applicable fees, commissions or discounts.
Our
ADSs are listed on the Nasdaq Capital Market, or Nasdaq, under the symbol “GENE” and our ordinary shares are listed on the
Australian Securities Exchange, or ASX, under the symbol “GTG.”
The
aggregate market value of our outstanding voting and non-voting common equity held by non-affiliates, based on the closing price of our
ADSs on the Nasdaq Capital Market of $2.79 on December 18, 2023, as calculated in accordance with General Instruction I.B.5. of Form
F-3, was $10,227,506. On December 18, 2023, the last sale price of our ordinary shares on the ASX was A$0.135 per share. We have sold
securities in the aggregate amount of $5,000,0000 pursuant to General Instruction I.B.5 of Form F-3 during the prior 12 calendar month
period that ends on, and includes, the date of this prospectus.
Investing
in these securities involves a high degree of risk. Please carefully consider the risks discussed in this prospectus under “Risk
Factors” in this prospectus, in any accompanying prospectus supplement and in the documents incorporated by reference in this prospectus
for a discussion of the factors you should carefully consider before deciding to purchase these securities.
Neither
the U.S. Securities and Exchange Commission, any U.S. state securities commission, nor any other foreign securities commission has approved
or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a
criminal offense.
The
date of this prospectus is ___________.
Table
of Contents
ABOUT
THIS PROSPECTUS
This
prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or SEC, using a “shelf”
registration process. Under this shelf registration process, we may sell our securities described in this prospectus in one or more offerings
up to a total dollar amount of $75,000,000. Each time we offer our securities, we will provide you with a supplement to this prospectus
that will describe the specific amounts, prices and terms of the securities we offer. The prospectus supplement may also add, update
or change information contained in this prospectus. This prospectus, together with applicable prospectus supplements and the documents
incorporated by reference in this prospectus and any prospectus supplements, includes all material information relating to this offering.
Please read carefully both this prospectus and any prospectus supplement together with additional information described below under “Where
You Can Find More Information” and “Incorporation of Certain Information by Reference.”
You
should rely only on the information contained in or incorporated by reference in this prospectus and any applicable prospectus supplement.
We have not authorized anyone to provide you with different or additional information. If anyone provides you with different or inconsistent
information, you should not rely on it. The information contained in this prospectus is accurate only as of the date of this prospectus,
regardless of the time of delivery of this prospectus or any sale of securities described in this prospectus. This prospectus is not
an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale
is not permitted. You should assume that the information appearing in this prospectus or any prospectus supplement, as well as information
we have previously filed with the SEC and incorporated by reference, is accurate as of the date on the front of those documents only.
Our business, financial condition, results of operations and prospects may have changed since those dates. This prospectus may not be
used to consummate a sale of our securities unless it is accompanied by a prospectus supplement.
Unless
otherwise indicated or the context otherwise requires, all references in this prospectus to the “Company,” “Genetic
Technologies,” “we,” “us” and “our” refer to Genetic Technologies Limited and its consolidated
subsidiaries. References to “ordinary shares,” “ADSs,” “preference shares,” “warrants”
and “share capital” refer to the ordinary shares, ADSs, preference shares, warrants and share capital, respectively, of the
Company.
Certain
figures included in this prospectus have been subject to rounding adjustments. Accordingly, figures shown as totals in certain tables
may not be an arithmetic aggregation of the figures that precede them.
For
investors outside of the United States: We have not taken any action to permit this offering or possession or distribution of this prospectus
in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves
about and to observe any restrictions relating to this offering and the distribution of this prospectus.
CAUTIONARY
STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This
prospectus contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this prospectus
can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “estimate,”
“expect,” “intend,” “plan,” “potential” and “should,” among others.
Forward-looking
statements appear in a number of places in this prospectus and include, but are not limited to, statements regarding our intent, belief,
or current expectations. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently
available to our management. Such statements are subject to substantial risks and uncertainties, and actual results may differ materially
from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to, those
identified under “Risk Factors.” In light of the significant uncertainties in these forward-looking statements, you should
not regard these statements as a guarantee by us or any other person that we will achieve our objectives and plans in any specified time
frame, or at all.
Forward-looking
statements include, but are not limited to, statements about:
|
● |
the
commercialization of our patented Multi Risk test launched in 2023 for cancer, cardiovascular and metabolic risk assessment tests
in the U.S and Australia; |
|
|
|
|
● |
our
competitive position in the molecular risk assessment and predictive testing area including a launch of the world’s first comprehensive
hereditary breast and ovarian cancer test; |
|
|
|
|
● |
our
continued collaboration plans to research, develop, and launch our product candidates; |
|
|
|
|
● |
the
size and growth potential of the current and new market opportunities for our products; |
|
|
|
|
● |
our
ability to raise additional capital; |
|
|
|
|
● |
our
expectations regarding our ability to obtain and maintain intellectual property protection; |
|
|
|
|
● |
our
ability to attract and retain qualified employees and key personnel; |
|
|
|
|
● |
our
ability to retain and maintain relationship with third party consultants and advisors and their ability to perform adequately; |
|
|
|
|
● |
our
estimates regarding future revenue, expenses and needs for additional financing; and |
|
|
|
|
● |
regulatory
developments in the United States, China and other jurisdictions and our compliance with such regulations. |
Forward-looking
statements speak only as of the date they are made, and we do not undertake any obligation to update them in light of new information
or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or
to reflect the occurrence of unanticipated events, except as may be required under applicable.
In
addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These
statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms
a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate
that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain,
and investors are cautioned not to unduly rely upon these statements.
You
should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration statement,
of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different
from what we expect. We qualify all of our forward-looking statements by these cautionary statements.
PROSPECTUS
SUMMARY
You
should read the following summary together with the more detailed information about us, the securities that may be sold from time to
time, and our financial statements and the notes thereto, all of which appear elsewhere in this prospectus or in the documents incorporated
by reference in this prospectus.
Overview
Genetic
Technologies Limited (ASX: GTG; Nasdaq: GENE) was founded in 1989 and listed on the ASX in 2000 and the NASDAQ in 2005. A global leader
in guideline driven genomics-based tests in health, wellness and serious disease through its geneType, EasyDNA, and Affinity DNA brands.
In addition to our patented GeneType polygenic based risk tests, our portfolio includes pharmacogenomics, Non-Invasive Prenatal Testing
(NIPT), carrier screen testing, oncogenetic diseases, and pet care.
GTG
offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The
company’s patented Polygenic Risk Scores (PRS) platform is a proprietary risk stratification tool developed over the past decade
integrating clinical and genetic risk delivering actionable outcomes for physicians and individuals. Sporadic disease occurs in people
with no family history of that disease and with no inherited change in their DNA making the risk difficult to predict with traditional
methods.
Leading
the world in risk prediction in Oncology, Cardiovascular, and Metabolic diseases, Genetic Technologies continues to develop our pipeline
of risk assessment products. The recent introduction of geneType Multi-Risk test risk assessments in one test covering breast cancer,
colorectal cancer, prostate cancer, ovarian cancer, coronary artery disease and Type-2 diabetes, has now been successfully expanded to
include Pancreatic Cancer, Melanoma, and Atrial Fibrillation. This first in class test non-invasive saliva-based test can predict a person’s
risk in up to 70% of annual mortalities and morbidities before onset. These tests along with integration of recently acquired DNA based
products underpin a broad and complementary portfolio of genomic based tests creating a significant competitive advantage.
GTG
has recently acquired two direct-to consumer e-commerce DNA testing businesses: EasyDNA (2021), with over 70 websites in 40 countries
and 6 brand identities; and Affinity DNA (2022), with a variety of DNA tests including lifestyle, health, and wellbeing genomics-based
tests, plus animal testing relating to allergies and intolerances via online marketplaces, including Amazon.
The
company operates in the USA, Europe, and Asia Pacific under various revenue models. For more information, please visit www.genetype.com.
In
May 2019, the Company announced that it had developed two new cancer risk assessment tests branded as GeneType for Breast Cancer and
GeneType for Colorectal Cancer. The new breast cancer test provides substantial improvement over the Company’s legacy breast cancer
test BREVAGenplus, by incorporating multiple additional clinical risk factors. This test will provide healthcare providers and
their patients with a 5-year and lifetime risk assessment of the patient developing breast cancer. The colorectal cancer test will provide
healthcare providers and their patients a 5-year, 10-year, and lifetime risk assessment of the patient developing colorectal cancer.
In
June 2020, the Company received US Patent No: US 10,683,549, Methods for assessing risk of developing breast cancer. The Company is the
first company in the world to successfully commercialize a polygenic risk test for breast cancer. The granted patent covers the Company’s
proprietary panels of single nucleotide polymorphisms (SNPs) and the combination of clinical and phenotypic risk models to create the
most comprehensive risk assessment tool on the market: GeneType for Breast Cancer.
In
February 2022 the Company received US Patent No: US 11,257,569, Methods of assessing risk of developing a severe response to Coronavirus
infection. The granted US patent covers the proprietary technology incorporated into GTG’s geneType COVID-19 Risk Test, which provides
a probability that a person will develop severe symptoms requiring hospitalization should they become infected.
During
the 2023 financial year the Company continued to develop other risk assessment tests, and improve existing tests across a range of diseases,
including:
|
● |
Breast
cancer |
|
● |
Pancreatic
Cancer |
|
● |
Melanoma |
|
● |
Colorectal
cancer |
|
● |
Ovarian
cancer |
|
● |
Prostate
cancer |
|
● |
Coronary
artery disease |
|
● |
Atrial
Fibrillation |
|
● |
Type
2 diabetes |
The
Company’s Genetic Testing Business
Following
the acquisition of Genetype AG in 1999 and the subsequent renaming to Genetic Technologies Limited, the Company focused on establishing
a genetic testing business, which over the following decade saw it become the largest provider of paternity and related testing services
in Australia. The Company’s service testing laboratory in Melbourne became the leading non-Government genetic testing service provider
in Australia. The genetic testing services of the Company expanded to include at certain times:
|
● |
Medical
testing |
|
● |
Animal
Testing |
|
● |
Forensic
Testing |
|
● |
Plant
Testing |
The
acquisition of GeneType AG also provided the Company with ownership rights to a potentially significant portfolio of issued patents.
During the intervening years, this portfolio has since been expanded by both organic growth and the acquisition of intellectual property
assets from third parties. The patent portfolio is constantly reviewed to ensure that the Company maintains potentially important patents
but at the same time keep costs to a minimum by no longer pursuing less commercially attractive and relevant intellectual property.
A
strategic alliance with Myriad Genetics Inc. delivered to the Company exclusive rights in Australia and New Zealand to perform DNA testing
for susceptibility to a range of cancers. In April 2003, the Company established its cancer susceptibility testing facility within its
Australian laboratory. In June 2003, this facility was granted provisional accreditation by the National Association of Testing Authorities,
Australia (“NATA”).
In
November 2003, the Company joined the world-wide genetic testing network GENDIA as the sole reference laboratory for the network in Australia
and New Zealand. GENDIA consists of more than 50 laboratories from around the world, each contributing expertise in their respective
disciplines to create a network capable of providing more than 2,000 different genetic tests. This provided the Company with the ability
to offer comprehensive testing services to its customer base in the Asia-Pacific region as well as increasing its exposure to other markets.
In
April 2010 the Company purchased various assets from Perlegen Sciences, Inc. of Mountain View, California, which included a breast cancer
non-familial risk assessment test, BREVAGen™. The Company then began validating the test in our Australian laboratory and initiated
the process for obtaining CLIA certification which would enable the Company to undertake the testing of samples received from the U.S.
market. By July 2010, a new U.S. subsidiary named Phenogen Sciences Inc. (renamed GeneType Inc. on April 3, 2023) had been incorporated
by the Company in Delaware to market and distribute the BREVAGen™ test across the United States.
In
October 2014, the Company announced the U.S. release of BREVAGenplus, an easy-to-use predictive risk test for the millions of
women at risk of developing sporadic, or non-hereditary, breast cancer, representing a marked enhancement in accuracy and broader patient
applicability, over its first generation BREVAGen™ product. The Company also made a pivotal change of sales and marketing emphasis
toward large comprehensive breast treatment and imaging centers, which are more complex entities with a longer sales cycle, but higher
potential.
GeneType
for Breast Cancer
The
identification in 2007 of a number of genetic biomarkers, consisting of single nucleotide polymorphisms (SNPs), each with an associated
small relative risk of breast cancer, led to the development of the first commercially available genetic risk test for sporadic breast
cancer, BREVAGen. The Company launched the product in the U.S. in June 2011. In October 2014, we released our next generation breast
cancer risk assessment test, BREVAGenplus. This new version of the test incorporated a 10-fold expanded panel of SNPs known to
be associated with the development of sporadic breast cancer, providing an increase in predictive power relative to its first-generation
predecessor test. In addition, the new test was clinically validated in a broader population of women including, African American and
Hispanic women. This increased the applicable market applicable to the first-generation test beyond Caucasian women, and simplified the
marketing process in medical clinics and breast health centers in the U.S.
The
expanded panel of SNPs incorporated into our breast cancer tests were identified from multiple large-scale genome-wide association studies
and subsequently tested in case-control studies utilizing specific Caucasian, African American and Hispanic patient samples.
BREVAGenplus
was a clinically validated, predictive risk test for sporadic breast cancer which examined a woman’s clinical risk factors,
combined with seventy-seven scientifically validated SNPs to allow for more personalized breast cancer risk assessment and risk management.
In
May 2019, we announced the development of our next generation breast cancer risk assessment test, ‘GeneType for Breast Cancer’.
The new breast cancer test provided substantial improvement over our legacy breast cancer test BREVAGenplus by incorporating key
clinical risk factors: family history, mammographic breast density and polygenic risk. This test will provide healthcare providers and
their patients with a 5-year and lifetime risk assessment of the patient developing breast cancer.
Germline
genetic testing for mutations in BRCA1 and BRCA2 allows for the identification of individuals at significantly increased risk for breast
and other cancers. However, such mutations are relatively rare in the general population and account for less than 10% of all breast
cancer cases. The remaining 90% of non-familial or sporadic breast cancer have to be defined by other genetic/clinical markers common
to the population at large and this is where we have focused our attention.
The
‘GeneType for Breast Cancer’ test is aimed at risk detection of non-BRCA related sporadic breast cancer (that is, for those
women who do not have an identified family history of breast cancer). Importantly, this means that the Company’s new test covers
95% of women.
In
June 2020, the Company received the approval for its U.S. patent number US 10,683,549, “Methods for Assessing Risk of Developing
Breast Cancer.” The granted patent covers the Company’s proprietary panels of single nucleotide polymorphisms (SNPs) and
the combination of clinical and phenotypic risk models to create the most comprehensive risk assessment tool on the market: GeneType
for Breast Cancer.
GeneType
for Colorectal Cancer
Next
generation risk assessments combine multiple clinical and genetic risk factors to better stratify individuals at increased risk of developing
disease. ‘GeneType for Colorectal Cancer’ incorporates the most impactful risk factors in order to define an individual’s
risk of developing colorectal cancer, so the healthcare provider can make screening and preventative care recommendations that are tailored
to their patient’s personalized risk.
Colorectal
cancer is the third most diagnosed cancer in the U.S., yet 1 in 3 adults are not receiving the appropriate colorectal cancer screening
for their age. In addition, rates of colorectal cancer among 20–49-year-olds is steadily increasing. Identifying patients who are
most at risk for colorectal cancer can lead to enhanced screening protocols and better outcomes. Most individuals diagnosed with colorectal
cancer do not have a significant family history of the disease. ‘GeneType for Colorectal Cancer’ evaluates the genometric
risk of developing colorectal cancer for men and women over age 30 who do not have a known pathogenic gene variant.
In
sporadic colorectal cancer, no single gene mutation is causal of disease. Rather, common DNA variations or SNPs, each contribute a small
but measurable risk of developing disease. ‘GeneType for Colorectal Cancer’ analyses a patient’s DNA for more than
40 SNPs that have been clinically validated in their association with colorectal cancer. By combining the effects of all of these SNPs
into a single polygenic risk score (PRS), ‘GeneType for Colorectal Cancer’ will provide a superior risk stratification over
standard risk assessments that incorporate only clinical factors.
‘GeneType
for Colorectal Cancer’ is clinically validated for men and women of 30 years of age or older and for individuals of Caucasian descent.
The Company intends to provide updates as it continuously improves its tests and add fully validated models for additional ethnicities.
Commercial
Launch of GeneType Multi-Risk Test
The
GeneType brand was re-launched globally in October 2021 following redevelopment of the Company’s websites, marketing and advertising,
media releases and announcements to the ASX and NASDAQ. The commercial launch of the GeneType Multi Risk Test in February 2022 included
the first phase launch to cover risk assessment for six serious diseases including breast, colorectal, prostate, and ovarian cancers,
coronary artery disease and Type-2 diabetes covering more than 50% of all serious diseases, all in one test sample. The GeneType Multi-Test
received simultaneous NATA accreditation and CMS certification in Australia and USA respectively. The first phase of the GeneType Multi-Test
became available to Health Care Professionals (HCPs) in February 2022.
In
March 2023 the Company announced that the geneType multi-risk test had been expanded to include three new diseases: Melanoma, pancreatic
cancer, and Atrial Fibrillation, taking the total number of diseases covered by the test to nine. Centers for Medicare & Medicaid
(CMS) approved the use of test for U.S. customers in March which was followed by the approval of test for the Australian market in September
2023 by the National Association of Testing Authority (NATA).
Commercial
Launch of GeneType Comprehensive Hereditary Breast and Ovarian Cancer (HBOC) Test
In
early 2023 we announced that the Company would develop and launch a ‘World First’ Comprehensive Risk Assessment Test which
evaluates a women’s risk of developing Breast and/or Ovarian Cancer either from a hereditary genetic mutation or from the far more
common familial or sporadic cancer. Combined with other clinical risk factors the test provides a comprehensive risk assessment in a
simple saliva test, this is scheduled for release in the U.S. in quarter 1 of the 2024 calendar year.
Global
Market Expansion Opportunities
In
November 2023, the Company announced its plan to launch its three brands, EasyDNA, Affinity DNA, and geneType, via the United Kingdom
(U.K.) pharmacy channel in April 2024. The U.K. National Pharmacy Association is driving an initiative to make at home testing accessible
in Pharmacy versus General Practice. Secondly, the Company is accelerating its plan to broaden our geneType brand into Southeast Asia
and in discussions on several initiatives with potential partners.
Scientific
Publications and Peer Reviewed Manuscripts
Over
the past 12 months our clinical and scientific team continue to lead the Company’s innovation, successfully publishing six peer
reviewed manuscripts. The data highlighting the clinical validity and utility of our patented geneType technology. Our talented team
continue to collaborate with world leading institutions to advance our innovation.
Direct-to-Consumer
Channel of Lifestyle Genetic Tests
The
Company’s acquisition of EasyDNA, in August 2021, gave us our direct-to-consumer channel for the sale and distribution of lifestyle
genetic tests. This was followed by the acquisition of Affinity DNA in August 2022. Both EasyDNA & Affinity DNA brand of tests can
be completed by the customer without the need to consult a healthcare professional. The laboratory testing of the EasyDNA and Affinity
DNA genetic tests are performed by contracted laboratories in the US, Europe and Australia. EasyDNA and Affinity DNA customers order
their tests online using our network of websites covering 40 countries.
Recent
Information
February
2023 Registered Offering
On
February 7, 2023, the Company announced the closing of its registered direct offering with several institutional investors for the purchase
and sale of 3,846,155 ADSs, each representing six hundred (600) ordinary shares of the Company, at a purchase price of $1.30 per ADS.
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering
were approximately $5 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.
MRFF
Grant
On
September 11, 2023, GTG announced that it had been named National Research Partner for a Medical Research Future Fund (MRFF) Genomics
Health Futures Mission Grant which was awarded to a group of renowned national and international research and charity organizations.
The grant will provide funding for the CASSOWARY Trial: a randomized controlled trial of the clinical utility and cost-effectiveness
of a multi-cancer polygenic risk score in general practice. The Cassowary Trial is a collaboration between international investigators
from GTG (Industry partner), University of Melbourne and Queen Mary University of London, The Royal Melbourne Hospital, Royal Marsden
NHS Foundation Trust, and the Daffodil Centre.
Share
Consolidation and ADS Ratio Change
On
November 22, 2023, we held our 2023 Annual General Meeting of shareholders (the “2023 Annual Meeting”). At the 2023 Annual
Meeting, our shareholders approved a share consolidation of all classes of our ordinary shares at a ratio of one (1) for one hundred
(100) such that each hundred ordinary shares of the Company would be combined into one ordinary share of the Company (the “Local
Consolidation”). In connection with the Local
Consolidation, the Company also simultaneously adjusted its ADS Ratio from the then-existing ratio of 1 ADS representing six hundred
(600) ordinary shares to one (1) ADS representing thirty (30) ordinary shares (the “Ratio Change”). Both the Local
Consolidation and the Ratio Change became effective at the open of trading on December 14, 2023. Our ordinary shares will continue
to be traded on the ASX, under the symbol “GTGDA”, from December 14 to December 22, 2023, before reverting to the symbol
“GTG’ on December 27, 2023. The ADSs will continue to be traded on The Nasdaq Stock Exchange under the symbol “GENE”.
On
the effective date, ADS holders were required on a mandatory basis to surrender their old ADSs to BNY Mellon for cancellation and exchange
at a rate of one (1) ‘new’ ADSs (CUSIP 37185R406) for every five (5) ‘old’ ADSs (CUSIP 37185R307) surrendered.
Holders of ADSs in the Direct Registration System or in brokerage accounts will have their ADSs automatically exchanged and need not
take any action. No fraction of an ADS will be issued. BNY Mellon has attempted to sell any fractions and distribute the cash proceeds
to holders. A cancellation fee of $0.022200 per Old ADS surrendered was charged.
Corporate
Information
Our
corporate headquarters and laboratory are located at 60-66 Hanover Street, Fitzroy, Victoria, 3065, Australia and our telephone number
is 61 3 8412 7000. The offices of our U.S. subsidiary, geneType Inc., are located at 1300 Baxter Street, Suite 157, Charlotte, North
Carolina 28269 and the office telephone number is (877) 992-7382. Our website address is www.genetype.com. The information in our website
is not incorporated by reference into this prospectus and should not be considered as part of this prospectus.
RISK
FACTORS
Investing
in our securities involves significant risk. The prospectus supplement applicable to each offering of our securities will contain a discussion
of the risks applicable to an investment in the Company. Prior to making a decision about investing in our securities, you should carefully
consider the specific factors discussed below and under the heading “Risk Factors” in the applicable prospectus supplement,
together with all of the other information contained or incorporated by reference in the prospectus supplement or appearing or incorporated
by reference in this prospectus. You should also consider the risks, uncertainties and assumptions discussed under the heading “Risk
Factors” included in our most recent Annual Report on Form 20-F and any subsequent Annual Reports on Form 20-F we file after the
date of this prospectus, and all other information contained in or incorporated by reference into this prospectus or the registration
statement of which this prospectus forms a part, as updated by our subsequent filings under the Securities Exchange Act of 1934, as amended
(the “Exchange Act”) and the risk factors and other information contained in any applicable prospectus supplement before
acquiring any of our securities. These risks might cause you to lose all or part of your investment in the offered securities.
Risks
Related to our Business
Volatile
economic or business conditions, including as a result of recent military conflicts and financial sector instability, may have a negative
impact on our business.
Continuing
concerns over economic and business prospects in the United States and other countries have contributed to increased volatility and diminished
expectations for the global economy. The conflict in Ukraine and the imposition of broad economic
sanctions on Russia could also raise energy or commodity prices and disrupt global markets. Unrest in Gaza and the recent conflicts within
that region continue to pose a threat and potential for war to expand, increasing market volatility across the globe. Recent bank failures,
including those of Credit Suisse, Silvergate Bank, Silicon Valley Bank, Signature Bank and First Republic Bank, may result in detrimental
effects to the global financial system. If the economic climate deteriorates, our business, including our access to patient samples
and the addressable market for diagnostic tests that we may successfully develop, as well as the financial condition of our suppliers
and our third-party payors, could be adversely affected, resulting in a negative impact on our business, financial condition, results
of operations and cash flows.
CAPITALIZATION
A
prospectus supplement or report on Form 6-K incorporated by reference into the registration statement of which this prospectus forms
a part will include information on our consolidated capitalization.
USE
OF PROCEEDS
Except
as otherwise provided in the applicable prospectus supplement, we intend to use the net proceeds from the sale of the securities offered
by this prospectus to support the introduction and distribution of our new products in the Canada, United States, and the United Kingdom;
for general product research and development, including of new, as well as improved, geneType risk assessment tests; expansion into other
geographical markets, working capital, and other general corporate purposes.
The
intended application of proceeds from the sale of any particular offering of securities using this prospectus will be described in the
accompanying prospectus supplement relating to such offering. The precise amount and timing of the application of these proceeds will
depend on our funding requirements and the availability and costs of other funds.
DESCRIPTION
OF SHARE CAPITAL AND CONSTITUTION
The
following description of our share capital is only a summary.
Our
constituent document or governing rules is a Constitution. Our Constitution is subject to the terms of the Listing Rules of the ASX and
the Australian Corporations Act 2001. The rights and restrictions attaching to ordinary shares are derived through a combination
of our Constitution, the common law applicable to Australia, the Listing Rules of the Australian Securities Exchange, the Corporations
Act 2001 and other applicable law. A general summary of some of the rights and restrictions attaching to ordinary shares are summarized
below. Each ordinary shareholder is entitled to receive notice of and to be present, to vote and to speak at general meetings.
We
encourage you to read our Constitution which is included as an exhibit to this registration statement of which this prospectus forms
a part. We do not have a limit on our authorized share capital and do not recognize the concept of par value under Australian law. Subject
to restrictions on the issue of securities in our Constitution, the Corporations Act 2001 and the Listing Rules of the Australian Securities
Exchange and any other applicable law, we may at any time issue shares and grant options or warrants on any terms, with the rights and
restrictions and for the consideration that the board of directors determine.
Dividends
Holders
of ordinary shares are entitled to receive such dividends as may be declared by the board of directors. All dividends are declared and
paid according to the amounts paid up on the shares in respect of which the dividend is paid. As of the date of this prospectus, there
have been no dividends paid to holders of ordinary shares.
Any
dividend unclaimed after a period of twelve years from the date of declaration of such dividend shall be paid to, and held by, the Public
Trustee of Victoria. The payment by the board of directors of any unclaimed dividend, interest or other sum payable on or in respect
of an ordinary share into a separate account shall not constitute us as a trustee in respect thereof.
Constitution
Our
constituent document is a Constitution which is similar in nature to the by-laws of a company incorporated under the laws of the U.S.
Our Constitution does not provide for or prescribe any specific objects or purposes of the Company. Our Constitution is subject to the
terms of the Listing Rules of the Australian Securities Exchange and the Corporations Act 2001. Our Constitution may be amended
or repealed and replaced by special resolution of shareholders, which is a resolution passed by at least 75% of the votes cast by shareholders
who vote by person or proxy at a duly convened shareholders meeting.
Shareholders
Meetings
We
must hold an annual general meeting within five months of the end of each fiscal year. Our end of fiscal year is currently June 30 each
year. At the annual general meeting, shareholders typically consider the annual financial report, directors’ report and auditor’s
report and vote on matters, including the election of directors, the appointment of the auditor (if necessary) and fixing the aggregate
limit of non-executive directors’ remuneration. We may also hold other meetings of shareholders from time to time. The annual general
meeting must be held in addition to any other meetings which we may hold.
The
board of directors may call and arrange a meeting of shareholders, when and where they decide. The directors must call a meeting of shareholders
when requested by shareholders who hold at least 5% of the votes that may be cast at the meeting or as otherwise required by the Corporations
Act 2001. Shareholders with at least 5% of the votes that may be cast at a meeting may also call and hold a general meeting, subject
to the notification requirements of the Corporations Act 2001.
Unless
applicable law or our Constitution requires a special resolution, a resolution of shareholders is passed if more than 50% of the votes
at the meeting are cast in favor of the resolution by shareholders in person or proxy entitled to vote upon the relevant resolution.
A special resolution is passed if the notice of meeting sets out the intention to propose the special resolution and it is passed if
at least 75% of the votes at the meeting are cast by shareholders in person or proxy entitled to vote upon the relevant resolution.
A
special resolution usually involves more important questions affecting the Company as a whole or the rights of some or all of our shareholders.
Special resolutions are required in a variety of circumstances under our Constitution and the Corporations Act 2001, including
without limitation:
|
● |
to
change our name; |
|
|
|
|
● |
to
amend or repeal and replace our Constitution; |
|
|
|
|
● |
to
approve the terms of issue of preference shares; |
|
|
|
|
● |
to
approve the variation of class rights of any class of shareholders; |
|
|
|
|
● |
to
convert one class of shares into another class of shares; |
|
|
|
|
● |
to
approve certain buy backs of shares; |
|
|
|
|
● |
to
approve a selective capital reduction of our shares; |
|
|
|
|
● |
to
approve financially assisting a person to acquire shares in the Company; |
|
|
|
|
● |
to
remove and replace our auditor; |
|
|
|
|
● |
to
change our company type; |
|
|
|
|
● |
with
the leave of an authorized Australian court, to approve our voluntary winding up; |
|
|
|
|
● |
to
confer on a liquidator of the Company either a general authority or a particular authority in respect of compensation arrangements
of the liquidator; and |
|
|
|
|
● |
to
approve an arrangement entered into between a company about to be, or in the course of being, wound up. |
Shareholder
Voting Rights
At
a general meeting, every shareholder present (in person or by proxy, attorney or representative) and entitled to vote has one vote on
a show of hands. Every shareholder present (in person or by proxy, attorney or representative) and entitled to vote has one vote per
fully paid ordinary share and that portion of a vote for any partly paid share that the amount paid on the partly paid share bears to
the total amounts paid and payable, on a poll. This is subject to any other rights or restrictions which may be attached to any shares.
In the case of an equality of votes on a resolution at a meeting (whether on a show of hands or on a poll), the chairman of the meeting
has a deciding vote in addition to any vote that the chairman of the meeting has in respect of that resolution.
Issue
of Shares and Changes in Capital
Subject
to our Constitution, the Corporations Act 2001, the Listing Rules of the Australian Securities Exchange and any other applicable law,
we may at any time issue shares and grant options or warrants on any terms, with preferred, deferred or other special rights and restrictions
and for the consideration and other terms that the directors determine. Our power to issue shares includes the power to issue bonus shares
(for which no consideration is payable to the Company), preference shares (including redeemable preference shares) and partly paid shares.
Pursuant
to the Listing Rules of the Australian Securities Exchange, our Board may in their discretion issue securities to persons who are not
related parties of our Company, without the approval of shareholders, if such issue, when aggregated with securities issued by us during
the previous 12-month period would be an amount that would not exceed 15% of our issued share capital at the commencement of the 12-month
period (or a combined limit of up to 25% of our issued share capital, subject to certain conditions, if prior approval for the additional
10% is obtained from shareholders at our annual meeting of shareholders). Other allotments of securities require approval by an ordinary
resolution of shareholders unless these other allotments of securities fall under a specified exception under the Listing Rules.
The
Company may issue preference shares, by approval of a special majority, which is a resolution of which notice has been given and that
has been passed by at least 75% of the voting rights represented at the meeting, in person, by proxy, or by written ballot and entitled
to vote on the resolution. There are no preference shares issued or allotted as at the date of this prospectus.
Subject
to the requirements of our Constitution, the Corporations Act 2001, the Listing Rules of the Australian Securities Exchange and any other
applicable law, we may:
|
● |
consolidate
or divide our share capital into a larger or smaller number by resolution passed by shareholders at a general meeting; |
|
|
|
|
● |
reduce
our share capital by special resolution passed by at least 75% of the votes cast by shareholders who vote by person or proxy at a
duly convened shareholders meeting (and are not otherwise excluded by law) provided that the reduction is fair and reasonable to
our shareholders as a whole, and does not materially prejudice our ability to pay creditors; |
|
|
|
|
● |
undertake
an equal access buyback of our ordinary shares by ordinary resolution of shareholders (although if we have bought back less than
10% of our shares over the period of the previous 12 months, shareholder approval may not be required); and |
|
|
|
|
● |
undertake
a selective buyback of certain shareholders’ shares by special resolution passed by at least 75% of the votes cast by shareholders
who vote by person or proxy at a duly convened shareholders meeting (and are not otherwise excluded by law), with no votes being
cast in favor of the resolution by any person whose shares are proposed to be bought back or by their associates. |
In
certain circumstances, including the division of a class of shares into further classes of shares, the issue of additional shares or
the issue of a new class of shares, we may require the approval of any class of shareholders whose rights are varied or are taken to
be varied by special resolution of shareholders generally and by special resolution of the holder of shares in that class whose rights
are varied or taken to be varied.
Dividends
may be paid on shares of one class but not another and at different rates for different classes.
Exchange
Controls
Australia
has largely abolished exchange controls on investment transactions. The Australian dollar is freely convertible into U.S. dollars. In
addition, there are currently no specific rules or limitations regarding the export from Australia of profits, dividends, capital or
similar funds belonging to foreign investors, except that certain payments to non-residents must be reported to the Australian Cash Transaction
Reports Agency, which monitors such transaction, and amounts on account of potential Australian tax liabilities may be required to be
withheld unless a relevant taxation treaty can be shown to apply.
Australian
Takeover Law
In
Australia, under the Corporations Act 2001, a person is prohibited from acquiring a “relevant interest” in the issued
voting shares in an Australia listed company if that acquisition results in any person’s voting power in that company increasing:
|
a) |
from
20% to more than 20%; or |
|
|
|
|
b) |
from
a starting point that is above 20% and below 90%, |
unless
the acquisition is made under one of the statutory exceptions set out in the Corporations Act 2001.
A
“relevant interest” is a wide and complex concept and includes the power to vote in relation to voting shares or to control
the disposal of voting shares.
The
most common exceptions under the Corporations Act 2001 which allow a person to obtain control of a Company are:
|
● |
an
off-market takeover bid, which is a written offer to all shareholders detailing the terms on which voting shares will be purchased,
which complies with the requirements of the Corporations Act 2001; |
|
|
|
|
● |
a
market takeover bid, which involves a broker standing in the market and purchasing all voting shares in a company at a certain price
on behalf of the bidder in accordance with the Corporations Act 2001; and |
|
|
|
|
● |
a
scheme of arrangement, which is a court-approved form of transaction between a company and its shareholders to bind a company’s
shareholder to a form of rearrangement of their rights and obligations. This form of transaction will only be binding if approved
by: |
|
|
○ |
over
50% of shareholders by number; and |
|
|
|
|
|
|
○ |
at
least 75% of the total number of votes cast by shareholders. |
Other
common exceptions used by persons who are not also seeking control include:
|
● |
where
shareholder approval by way of ordinary resolution (i.e. over 50%) is obtained for acquisitions of shares above 20%. The bidder and
the shareholders from whom the acquisition is to be made would be excluded from voting on such a resolution; and |
|
|
|
|
● |
an
exception known as “creep” in which a person who has a voting power in the Company of at least 19% throughout the 6 months
before the acquisition may acquire up to a further 3% of the Company’s shares over the next six months. |
Substantial
Shareholder Notices
A
person must also give notice to the Company and the ASX if they, acquire an interest in 5% or more in the voting shares of the Company
(Substantial Holding). Further notice of any changes of a Substantial Holding by 1% or more within 2 days of the change or within
24 hours is the person has submitted a takeover bid or if the person ceases to be a substantial holder.
Proportional
Takeover Provisions
A
proportional takeover bid is an off-market offer or bid to purchase a proportion of securities in a certain bid class (Proportional
Takeover Bid).
Section
648G of the Corporations Act 2001 allows a company to include in its constitution provisions preventing the registration of a
transfer of securities resulting from a Proportional Takeover Bid, unless the relevant holders of the securities approve the bid (Proportional
Takeover Provisions). Under the Corporations Act Proportional Takeover Provisions may only apply for a maximum period of three years,
unless renewed earlier by shareholder approval passed by way of a special resolution. A special resolution requires approval of 75% of
the votes cast by shareholders present and eligible to vote (in person, by proxy, by attorney or, in the case of a corporate Shareholder,
by a corporate representative).
The
Company’s Constitution contains Proportional Takeover Provisions. Under these provisions where an offer has been made under a Proportional
Takeover Bid for the securities in the Company the Directors must convene a meeting of the holders of the relevant class of securities
to vote on a resolution to approve that bid. The meeting must be held and the resolution voted on at least 14 days before the last day
of the bid period. To be passed the resolution must be approved by a majority of votes at the meeting excluding votes by the bidder and
its associates.
However,
under the Corporations Act if the meeting is not held in time then a resolution to approve the Proportional Takeover Bid will be deemed
to have been passed. If the resolution to approve the takeover bid is passed (or deemed to have been passed) the transfer of Shares resulting
from the acceptance of an offer under the bid will be permitted and the transfer will be registered.
If
the resolution is rejected the registration of any transfers of securities arising from an offer under the Proportional Takeover Bid
will be prohibited and the bid will be deemed to be withdrawn.
The
Foreign Acquisitions and Takeovers Act 1975
Under
Australian law, in certain circumstances foreign persons are prohibited from acquiring more than a limited percentage in an Australian
company without notice from the Australian Treasurer confirming that there is no objection to the Transaction (FIRB Approval).
These limitations are set forth in the Australian Foreign Acquisitions and Takeovers Act 1975 (Cth), or the FATA.
Under
the FATA, as currently in effect, any foreign person (excluding foreign government investors), together with associates, or parties acting
in concert, is prohibited from holding an interest of 20% or more in any Australian company if either the value of the Company’s
total assets or total issued securities exceeds A$310 million (or A$1,339 million in the case of investors from the U.S. and other countries
with which Australia has a free trade agreement) without first obtaining FIRB Approval. “Associates” is a broadly defined
term under the Takeovers Act and includes:
|
● |
spouses,
lineal ancestors and descendants, and siblings; |
|
|
|
|
● |
partners,
officers of companies, the company, employers and employees, and corporations; |
|
|
|
|
● |
their
shareholders related through substantial shareholdings or voting power; |
|
|
|
|
● |
corporations
whose directors are controlled by the person, or who control a person; and |
|
|
|
|
● |
associations
between trustees and substantial beneficiaries of trust estates. |
The
determination of whether a person has acquired a 20% interest must be conducted on a fully diluted basis as well as an undiluted basis.
This means that the interest of other convertible securities like options, warrants and units should be included when determining a person’s
percentage on a fully diluted basis.
Foreign
government investors will require FIRB Approval prior to holding a direct interest in the Company irrespective of the value of the consideration,
or the value of the Company’s total assets or total issued securities. The term “direct interest” means an interest
of at least 10%, or an interest of at least 5% if the person who acquires the interest has entered a legal arrangement relating to the
businesses of the person and the Company beyond the supply of goods or services on ordinary commercial terms; or an interest of any percentage
in the Company if the person who acquired the interest is in a position to influence or participate in the central management and control
or determine the policy of the Company i.e. if board representation or special veto rights beyond those afforded to shareholders are
acquired.
If
the necessary approvals are not obtained, the Treasurer may make orders including orders requiring the acquirer to dispose of the securities
it has acquired within a specified period of time. Significant criminal and civil penalties may also apply if a person proceeds without
FIRB Approval, where it is required in breach of the FATA.
Additionally,
if a foreign person (excluding foreign government investors) acquires a holding of a direct interest in the Company the Treasurer has
the power to “call in” such acquisitions anytime over a period of 10 years following the acquisition unless FIRB Approval
has voluntarily been obtained.
Once
“called in”, an investment will be reviewed under the national security test to determine if it raises national security
concerns, consistent with the same process as those investors who notify on a mandatory basis. So foreign persons would still have the
opportunity to make submissions.
While
it is expected that the overwhelming majority of investments will not be called-in for review guidance has been released outlining the
investment areas in which investors are encouraged to voluntarily apply for FIRB Approval to obtain certainty on the likelihood of the
Treasurer operating the call in power. Relevantly, voluntary notification is encouraged for investments in pathology providers that would
result in the applicant holding sensitive personal information (including medical and personal contact details) relating to greater than
100,000 Australian individuals.
To
obtain FIRB Approval an application will need to be made setting out (amongst other things) the proposal, the person and their upstream
ownership details and the relevant particulars of the acquisition/shareholding. The Australian Treasurer then has 30 days to consider
the application and make a decision. However, the Australian Treasurer may extend the period by up to a further 90 days by publishing
an interim order. Applications are assessed against a national interest test, which includes national security, competition, data security,
economic and government policies including taxation, unless FIRB Approval is voluntarily obtained, in which case just the national security
test is applied.
If
the level of foreign ownership exceeds 40% at any time, we would be considered a foreign person under the Takeovers Act. In such event,
we would be required to obtain the approval of the Australian Treasurer for us, together with our associates, to acquire (i) more than
20% of an Australian company or business with assets totaling over A$266 million; or (ii) any direct or indirect ownership in Australian
residential real estate and certain non-residential real estate.
The
percentage of foreign ownership in us would also be included determining the foreign ownership of any Australian company or business
in which it may choose to invest. Since we have no current plans for any such acquisition and do not own any property, any such approvals
required to be obtained by us as a foreign person under the Takeovers Act will not affect our current or future ownership or lease of
property in Australia.
Our
Constitution does not contain any additional limitations on a non-resident’s right to hold or vote our securities.
Australian
law requires any off-market transfer of our shares to be made in writing. Otherwise, while our ordinary shares remain listed on the ASX,
transfers take place electronically through the ASX’s exchange process and requirements. No stamp duty will be payable in Australia
on the transfer of ADSs.
Liquidation
Rights
After
satisfaction of the claims of creditors, preferential payments to holders of outstanding preference shares and subject to any special
rights or restrictions attached to shares, on a winding up, any available assets must be used to repay the capital contributed by the
shareholders and any surplus must be distributed among the shareholders in proportion to the number of fully paid shares held by them.
For this purpose, a partly paid share is treated as a fraction of a share equal to the proportion which the amount paid bears to the
total issue price of the share before the winding up began.
If
we experience financial problems, the directors may appoint an administrator to take over our operations to see if we can come to an
arrangement with our creditors. If we cannot agree with our creditors, Genetic Technologies Limited may be wound up.
A
receiver, or receiver and manager, may be appointed by order of a court or under an agreement with a secured creditor to take over some
or all of the assets of a company. A receiver may be appointed, for example, because an amount owed to a secured creditor is overdue.
We
may be wound up by order of a court, or voluntarily if our shareholders pass a special resolution to do so. A liquidator is appointed
when a court orders a company to be wound up or the shareholders of a company pass a resolution to wind up the company. A liquidator
is appointed to administer the winding up of a company.
DESCRIPTION
OF AMERICAN DEPOSITARY SHARES
The
Bank of New York Mellon, as depositary, will register and deliver ADSs. Each ADS represents 30 ordinary shares (or a right to receive
30 ordinary shares) deposited with HSBC Bank Australia Limited, as custodian for the depositary. Each ADS also represents any other securities,
cash or other property which may be held by the depositary. The depositary’s corporate trust office at which the ADSs are administered,
and its executive offices, are located at 240 Greenwich Street, New York, New York 10286.
You
may hold ADSs either (A) directly (i) by having an American depositary receipt, which is a certificate evidencing a specific number of
ADSs, registered in your name, or (ii) by holding ADSs in the Direct Registration System, or (B) indirectly through your broker or other
financial institution. If you hold ADSs directly, you are an ADS holder. This description assumes you hold the ADSs directly. If you
hold the ADSs indirectly, you must rely on the procedures of your broker or other financial institution to assert the rights of ADR holders
described in this section. You should consult with your broker or financial institution to find out what those procedures are.
The
Direct Registration System is a system administered by DTC pursuant to which the depositary may register the ownership of uncertificated
ADSs, which ownership shall be confirmed by periodic statements issued by the depositary to the ADS holders entitled thereto.
As
an ADS holder, we will not treat you as one of our shareholders and you will not have shareholder rights. Australian law governs shareholder
rights. The depositary will be the holder of the shares underlying the ADSs. As a holder of ADSs, you will have ADS holder rights. A
deposit agreement among us, the depositary and you, as an ADS holder, and the beneficial owners of ADSs set out ADS holder rights as
well as the rights and obligations of the depositary. New York law governs the deposit agreement and the ADSs.
The
following is a summary of the material provisions of the deposit agreement. For more complete information, you should read the entire
deposit agreement and the form of American depositary receipt. Directions on how to obtain copies of those documents are provided under
“Where You Can Find Additional Information.”
Dividends
and Other Distributions
If
we Pay a Dividend or Other Distribution, How Will You Receive Dividends and Other Distributions on the Shares?
In
the event that we pay a cash dividend or make another distribution, the depositary has agreed to pay to you the cash dividends or other
distributions it or the custodian receives on shares or other deposited securities, after deducting its fees and expenses. You will receive
these distributions in proportion to the number of shares the ADSs represent.
|
● |
Cash.
The depositary will convert any cash dividend or other cash distribution we pay on the shares into U.S. dollars, if it can do so
on a reasonable basis and can transfer the U.S. dollars to the United States. If that is not possible or if any government approval
is needed and cannot be obtained, the deposit agreement allows the depositary to distribute the foreign currency only to those ADR
holders to whom it is possible to do so. It will hold the foreign currency it cannot convert for the account of the ADS holders who
have not been paid. It will not invest the foreign currency and it will not be liable for any interest. |
|
|
|
|
|
Before
making a distribution, any withholding taxes, or other governmental charges that must be paid will be deducted. The depositary will
distribute only whole U.S. dollars and cents and will round fractional cents to the nearest whole cent. If exchange rates fluctuate
during a time when the depositary cannot convert the foreign currency, you may lose some or all of the value of the distribution. |
|
|
|
|
● |
Shares.
The depositary may distribute additional ADSs representing any shares we distribute as a dividend or free distribution. The depositary
will only distribute whole ADSs. It will sell shares which would require it to deliver a fractional ADS and distribute the net proceeds
in the same way as it does with cash. If the depositary does not distribute additional ADSs, the outstanding ADSs will also represent
the new shares. |
|
|
|
|
● |
Rights
to Purchase Additional Shares. If we offer holders of our securities any rights to subscribe for additional shares or any
other rights, the depositary may make these rights available to you. If the depositary decides it is not legal and practical to make
the rights available but that it is practical to sell the rights, the depositary will use reasonable efforts to sell the rights and
distribute the proceeds in the same way as it does with cash. The depositary will allow rights that are not distributed or sold to
lapse. In that case, you will receive no value for them. |
|
|
|
|
|
If
the depositary makes rights available to you, it will exercise the rights and purchase the shares on your behalf. The depositary
will then deposit the shares and deliver ADSs to you. It will only exercise rights if you pay it the exercise price and any other
charges the rights require you to pay. |
|
|
U.S.
securities laws may restrict transfers and cancellation of the ADSs represented by shares purchased upon exercise of rights. For
example, you may not be able to trade these ADSs freely in the United States. In this case, the depositary may deliver restricted
depositary shares that have the same terms as the ADSs described in this section except for changes needed to put the necessary restrictions
in place. |
|
|
|
|
● |
Other
Distributions. The depositary will send to you anything else we distribute on deposited securities by any means it thinks is
legal, fair and practical. If it cannot make the distribution in that way, the depositary has a choice. It may decide to sell what
we distributed and distribute the net proceeds, in the same way as it does with cash. Or, it may decide to hold what we distributed,
in which case ADSs will also represent the newly distributed property. However, the depositary is not required to distribute any
securities (other than ADSs) to you unless it receives satisfactory evidence from us that it is legal to make that distribution. |
The
depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any ADS holders. We
have no obligation to register ADSs, shares, rights or other securities under the Securities Act. We also have no obligation to take
any other action to permit the distribution of ADSs, shares, rights or anything else to ADS holders. This means that you may not receive
the distributions we make on our shares or any value for them if it is illegal or impractical for us to make them available to you.
Deposit,
Withdrawal and Cancellation
How
Are ADSs Issued?
The
depositary will deliver ADSs if you or your broker deposits shares or evidence of rights to receive shares with the custodian. Upon payment
of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will register
the appropriate number of ADSs in the names you request and will deliver the ADSs to or upon the order of the person or persons entitled
thereto.
How
Do ADS Holders Cancel an ADS?
You
may turn in the ADSs at the depositary’s corporate trust office. Upon payment of its fees and expenses and of any taxes or charges,
such as stamp taxes or stock transfer taxes or fees, the depositary will deliver the shares and any other deposited securities underlying
the ADSs to you or a person you designate at the office of the custodian. Or, at your request, risk and expense, the depositary will
deliver the deposited securities at its corporate trust office, if feasible.
Voting
Rights
How
Do You Vote?
You
may instruct the depositary to vote the deposited securities, but only if we ask the depositary to ask for your instructions. Otherwise,
you won’t be able to exercise your right to vote unless you withdraw the shares. However, you may not know about the meeting enough
in advance to withdraw the shares.
If
we ask for your instructions, the depositary will notify you of the upcoming vote and arrange to deliver our voting materials to you.
The materials will (1) describe the matters to be voted on and (2) explain how you may instruct the depositary to vote the shares or
other deposited securities underlying the ADSs as you direct. For instructions to be valid, the depositary must receive them on or before
the date specified. The depositary will try, as far as practical, subject to the laws of Australia and our Constitution, to vote or to
have its agents vote the shares or other deposited securities as you instruct. The depositary will only vote or attempt to vote as you
instruct or as described below. Notwithstanding anything to the contrary contained in the deposit agreement, the depositary will not
exercise a discretionary proxy in respect of the deposited securities for which it has not timely received instructions.
If
we ask the depositary to solicit your instructions but the depositary does not receive voting instructions from you by the specified
date, it will consider you to have authorized and directed it to give a discretionary proxy to a person designated by us to vote the
number of ordinary shares represented by your ADSs. The depositary will give a discretionary proxy in those circumstances to vote on
all questions as to be voted upon unless we notify the depositary that:
|
● |
we
do not wish to receive a discretionary proxy; |
|
|
|
|
● |
there
is substantial shareholder opposition to the particular questions; or |
|
|
|
|
● |
the
particular question would have an adverse impact on our shareholders. |
We
are required to notify the depositary if one or more of the conditions specified above exists.
We
cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote your shares.
In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying
out voting instructions. This means that you may not be able to exercise your right to vote and there may be nothing you can do if your
shares are not voted as you requested.
In
order to give you a reasonable opportunity to instruct the depositary as to the exercise of voting rights relating to deposited securities,
if we request the depositary to act, we will try to give the depositary notice of any such meeting and details concerning the matters
to be voted upon sufficiently in advance of the meeting date.
Fees
and Expenses
Persons
Depositing or Withdrawing Shares Must Pay:
|
|
For: |
|
|
|
|
|
● |
US$5.00
(or less) per 100 ADSs (or portion of 100 ADSs) |
|
● |
Issuance
of ADSs, including issuances resulting from a distribution of shares or rights or other property |
|
|
|
● |
Cancellation
of ADSs for the purpose of withdrawal, including if the deposit agreement terminates |
● |
US$0.02
(or less) per ADS |
|
● |
Any
cash distribution to you |
● |
A
fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been deposited
for issuance of ADSs |
|
● |
Distribution
of securities distributed to holders of deposited securities which are distributed by the depositary to ADS holders |
● |
Expenses
of the depositary |
|
● |
Cable,
telex and facsimile transmissions (when expressly provided in the deposit agreement) |
|
|
|
● |
Converting
foreign currency to U.S. dollars |
● |
Taxes
and other governmental charges the depositary or the custodian have to pay on any ADS or share underlying an ADS, for example, stock
transfer taxes, stamp duty or withholding taxes |
|
● |
As
necessary |
● |
Any
charges incurred by the depositary or its agents for servicing the deposited securities |
|
● |
As
necessary |
● |
US$0.02
(or less) per ADS per year |
|
● |
Depositary
services |
The
depositary collects its fees for issuance and cancellation of ADSs directly from investors depositing shares or surrendering ADSs for
the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors
by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary
may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging
the book-entry system accounts of participants acting for them. The depositary may generally refuse to provide fee-attracting services
until its fees for those services are paid.
Payment
of Taxes
You
will be responsible for any taxes or other governmental charges payable on the ADSs or on the deposited securities represented by any
of the ADSs. The depositary may refuse to register any transfer of the ADSs or allow you to withdraw the deposited securities represented
by the ADSs until such taxes or other charges are paid. It may apply payments owed to you or sell deposited securities represented by
the ADSs to pay any taxes owed and you will remain liable for any deficiency. If the depositary sells deposited securities, it will,
if appropriate, reduce the number of ADSs to reflect the sale and pay to you any proceeds, or send to you any property, remaining after
it has paid the taxes.
Reclassifications,
Recapitalizations and Mergers If
we: |
|
Then: |
● |
Change
the nominal or par value of our shares Reclassify, split up or consolidate any of the deposited securities |
|
● |
The
securities received by the depositary will become deposited securities. Each ADS will automatically represent its equal share of
the new deposited securities. |
|
|
|
|
|
● |
Recapitalize,
reorganize, merge, liquidate, sell all or substantially all of our assets, or take any similar action |
|
● |
The
depositary may, and will if we ask it to, deliver new ADRs or ask you to surrender your outstanding ADRs in exchange for new ADRs
identifying the new deposited securities. |
Amendment
and Termination
How
May the Deposit Agreement Be Amended?
We
may agree with the depositary to amend the deposit agreement and the ADSs without your consent for any reason. If an amendment adds or
increases fees or charges, except for taxes and other governmental charges or expenses of the depositary for registration fees, facsimile
costs, delivery charges or similar items, or prejudices a substantial right of ADS holders, it will not become effective for outstanding
ADSs until 30 days after the depositary notifies ADS holders of the amendment. At the time an amendment becomes effective, you are
considered, by continuing to hold the ADS, to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended.
How
May the Deposit Agreement Be Terminated?
The
depositary will terminate the deposit agreement at our direction by mailing a notice of termination to the ADS holders then outstanding
at least 90 days prior to the date fixed in such notice for such termination. The depositary may also terminate the deposit agreement
by mailing a notice of termination to us and the ADS holders then outstanding if at any time 90 days shall have expired after the depositary
shall have delivered to our company a written notice of its election to resign and a successor depositary shall not have been appointed
and accepted its appointment.
After
termination, the depositary and its agents will do the following under the deposit agreement but nothing else: collect dividends and
other distributions on the deposited securities, sell rights and other property, and deliver shares and other deposited securities upon
cancellation of ADSs. One year after termination, the depositary may sell any remaining deposited securities by public or private sale.
After that, the depositary will hold the money it received on the sale, as well as any other cash it is holding under the deposit agreement
for the pro rata benefit of the ADS holders that have not surrendered their ADSs. It will not invest the money and has no liability
for interest. The depositary’s only obligations will be to account for the money and other cash. After termination our only obligations
will be to indemnify the depositary and to pay fees and expenses of the depositary that we agreed to pay.
Limitations
on Obligations and Liability
Limits
on Our Obligations and the Obligations of the Depositary; Limits on Liability to Holders of ADSs
The
deposit agreement expressly limits our obligations and the obligations of the depositary. It also limits our liability and the liability
of the depositary. We and the depositary:
|
● |
are
only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith; |
|
|
|
|
● |
are
not liable if either of us is prevented or delayed by law or circumstances beyond our control from performing our obligations under
the deposit agreement; |
|
|
|
|
● |
are
not liable if either of us exercises discretion permitted under the deposit agreement; |
|
|
|
|
● |
have
no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the deposit agreement on your behalf or
on behalf of any other party if it involves expenses or liability unless you furnish satisfactory indemnity; and |
|
|
|
|
● |
may
rely upon the advice of or information from legal counsel, accountants, any person presenting shares for deposit and any other holder
of ADSs or any other person if we believe in good faith such person is competent to give such advice or information. |
|
|
|
|
● |
In
the deposit agreement, we and the depositary agree to indemnify each other under certain circumstances. |
Requirements
for Depositary Actions
Before
the depositary will deliver or register a transfer of an ADS, make a distribution on an ADS, or permit withdrawal of shares, the depositary
may require:
|
● |
payment
of stock transfer or other taxes or other governmental charges and transfer or registration fees charged by third parties for the
transfer of any shares or other deposited securities; |
|
|
|
|
● |
satisfactory
proof of the identity and genuineness of any signature or other information it deems necessary; and |
|
|
|
|
● |
compliance
with regulations it may establish, from time to time, consistent with the deposit agreement, including presentation of transfer documents. |
The
depositary may refuse to deliver ADSs or register transfers of ADSs generally when the transfer books of the depositary or our transfer
books are closed or at any time if the depositary or we think it advisable to do so.
Your
Right to Receive the Shares Underlying Your ADRs
You
have the right to cancel the ADSs and withdraw the underlying shares at any time except:
|
● |
When
temporary delays arise because: (i) the depositary has closed its transfer books or we have closed our transfer books; (ii) the transfer
of shares is blocked to permit voting at a shareholders’ meeting; or (iii) we are paying a dividend on our shares. |
|
|
|
|
● |
When
you or other ADS holders seeking to withdraw shares owe money to pay fees, taxes and similar charges. |
|
|
|
|
● |
When
it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the
withdrawal of shares or other deposited securities. |
|
|
|
|
● |
This
right of withdrawal may not be limited by any other provision of the deposit agreement. |
DESCRIPTION
OF PREFERENCE SHARES
Subject
to any limitations under the Corporations Act, ASX Listing Rules or the Constitution, our board of directors may issue preference shares
with any preferential rights, privileges or conditions. The rights and restrictions attaching to any preference shares are set out in
our Constitution or in a special resolution of shareholders. Our Constitution does not limit the amount of preference shares that we
may issue.
We
do not have any preference shares outstanding as of the date of this prospectus. In the future we may issue preference shares that could
be converted into ordinary shares. A prospectus supplement will contain and describe the material terms of any preference shares that
we offer to the public in the United States, along with any material U.S. federal or Australian income tax considerations relating to
the offer of such preference shares.
Consistent
with the ASX Listing Rules and our Constitution, any preference shares issued by us must confer on the holders of those preference shares:
|
● |
the
same rights as holders of ordinary shares to receive notices of general meetings, other notices, reports and accounts and to attend
general meetings; |
|
|
|
|
●
|
the
right to vote in each of the following circumstances and in no others: (i) in a period during which a dividend (or part of a dividend)
in respect of the share is in arrears; (ii) on a proposal to reduce our share capital; (iii) on a resolution to approve the terms
of a buy-back agreement; (iv) on a proposal that affects rights attached to the shares; (v) on a proposal to wind up our company;
(vi) on a proposal for the disposal of the whole of our property, business and undertaking; (vii) during the winding up of our company;
(viii) subject to the ASX Listing Rules and Nasdaq, in any additional circumstances specified in the terms of issue of such preference
shares by us relating to the shares upon issuance; |
|
|
|
|
●
|
a
dividend in preference to holders of ordinary shares; and |
|
|
|
|
●
|
a
return of capital in preference to holders of ordinary shares if we were to be wound up. |
The
ASX Listing Rules impose certain limitations on the issuance of preference shares by companies such as our company that are listed on
ASX, including:
|
● |
any
dividends on preference shares must be at a commercial rate; and |
|
|
|
|
● |
any
anti-dilution rights must be limited to the right to adjust the number of ordinary shares into which preference shares convert in
the event of a share split or consolidation (i.e., reverse stock split), a bonus or entitlement issue (e.g., stock
dividend), or other capital reconstruction. |
Further,
the Corporations Act places certain limitations on payment of dividends, including preferred dividends. A right to receive dividends
on a preference share may be expressed to be cumulative where it cannot be paid due to legal limitations.
DESCRIPTION
OF WARRANTS
We
may issue and offer warrants under the material terms and conditions described in this prospectus and any accompanying prospectus supplement.
The accompanying prospectus supplement may add, update or change the terms and conditions of the warrants as described in this prospectus.
We
may issue warrants to purchase our ordinary shares represented by ADSs. Warrants may be issued independently or together with any securities
and may be attached to or separate from those securities. The warrants may be issued under warrant or subscription agreements to be entered
into between us and a bank or trust company, as warrant agent, all of which will be described in the prospectus supplement relating to
the warrants we are offering. The warrant agent will act solely as our agent in connection with the warrants and will not have any obligation
or relationship of agency or trust for or with any holders or beneficial owners of warrants.
The
particular terms of the warrants, the warrant or subscription agreements relating to the warrants and the warrant certificates representing
the warrants will be described in the applicable prospectus supplement, including, as applicable:
|
● |
the
title of such warrants; |
|
|
|
|
● |
the
aggregate number of such warrants; |
|
|
|
|
● |
the
price or prices at which such warrants will be issued and exercised; |
|
|
|
|
● |
the
currency or currencies in which the price of such warrants will be payable; |
|
|
|
|
● |
the
date on which the right to exercise such warrants shall commence and the date on which such right shall expire; |
|
|
|
|
● |
if
applicable, the minimum or maximum amount of such warrants which may be exercised at any one time; |
|
|
|
|
● |
if
applicable, the designation and terms of the securities with which such warrants are issued and the number of such warrants issued
with each such security; |
|
|
|
|
● |
if
applicable, the date on and after which such warrants and the related securities will be separately transferable; |
|
|
|
|
● |
if
applicable, any provisions for cashless exercise of the warrants; |
|
|
|
|
● |
if
applicable; any exercise limitations with respect to the ownership limitations by the holder exercising the warrant; |
|
|
|
|
● |
information
with respect to book-entry procedures, if any; |
|
|
|
|
● |
any
material Australian and United States federal income tax consequences; |
|
|
|
|
● |
the
anti-dilution provisions of the warrants, if any; and |
|
|
|
|
● |
any
other terms of such warrants, including terms, procedures and limitations relating to the exchange and exercise of such warrants. |
Holders
of warrants will not be entitled, solely by virtue of being holders, to vote, to consent, to receive dividends, to receive notice as
shareholders with respect to any meeting of shareholders for the election of directors or any other matters, or to exercise any rights
whatsoever as a holder of the equity securities purchasable upon exercise of the warrants.
The
description in the applicable prospectus supplement of any warrants we offer will not necessarily be complete and will be qualified in
its entirety by reference to the applicable warrant agreement and warrant certificate, which will be filed with the SEC if we offer warrants.
For more information on how you can obtain copies of the applicable warrant agreement if we offer warrants, see “Where You Can
Find More Information” and “Incorporation of Certain Information by Reference.” We urge you to read any applicable
prospectus supplement and the applicable warrant agreement and form of warrant certificate in their entirety.
DESCRIPTION
OF UNITS
We
may issue units comprised of one or more of the other securities described in this prospectus in any combination. Each unit will be
issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have
the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide
that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified
date.
The
applicable prospectus supplement will describe:
|
● |
the
designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those
securities may be held or transferred separately; |
|
|
|
|
●
|
any
unit agreement under which the units will be issued; |
|
|
|
|
●
|
any
provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units; and |
|
|
|
|
●
|
whether
the units will be issued in fully registered or global form. |
The
applicable prospectus supplement will describe the terms of any units. The preceding description and any description of units in the
applicable prospectus supplement does not purport to be complete and is subject to and is qualified in its entirety by reference to the
unit agreement and, if applicable, collateral arrangements and depositary arrangements relating to such units. For more information on
how you can obtain copies of the applicable unit agreement if we offer units, see “Where You Can Find More Information” and
“Incorporation of Certain Information by Reference.” We urge you to read the applicable unit agreement and any applicable
prospectus supplement in their entirety.
PLAN
OF DISTRIBUTION
The
securities being offered by this prospectus may be sold:
|
● |
through
agents; |
|
|
|
|
● |
to
or through one or more underwriters on a firm commitment or agency basis; |
|
|
|
|
● |
through
put or call option transactions relating to the securities; |
|
|
|
|
● |
to
or through dealers, who may act as agents or principals, including a block trade (which may involve crosses) in which a broker or
dealer so engaged will attempt to sell as agent but may position and resell a portion of the block as principal to facilitate the
transaction; |
|
|
|
|
● |
through
privately negotiated transactions; |
|
|
|
|
● |
purchases
by a broker or dealer as principal and resale by such broker or dealer for its own account pursuant to this prospectus; |
|
|
|
|
● |
directly
to purchasers, including our affiliates, through a specific bidding or auction process, on a negotiated basis or otherwise; to or
through one or more underwriters on a firm commitment or best efforts basis; |
|
|
|
|
● |
exchange
distributions and/or secondary distributions; |
|
|
|
|
● |
ordinary
brokerage transactions and transactions in which the broker solicits purchasers; |
|
|
|
|
● |
in
“at-the-market” offerings, within the meaning of Rule 415(a)(4) of the Securities Act to or through a market maker or
into an existing trading market, on an exchange or otherwise; |
|
|
|
|
● |
transactions
not involving market makers or established trading markets, including direct sales or privately negotiated transactions; |
|
● |
transactions
in options, swaps or other derivatives that may or may not be listed on an exchange; |
|
|
|
|
● |
through
any other method permitted pursuant to applicable law; or |
|
|
|
|
●
|
through
a combination of any such methods of sale. |
At
any time a particular offer of the securities covered by this prospectus is made, a revised prospectus or prospectus supplement, if required,
will be distributed which will set forth the aggregate amount of securities covered by this prospectus being offered and the terms of
the offering, including the name or names of any underwriters, dealers, brokers or agents, any discounts, commissions, concessions and
other items constituting compensation from us and any discounts, commissions or concessions allowed or re-allowed or paid to dealers.
Such prospectus supplement, and, if necessary, a post-effective amendment to the registration statement of which this prospectus is a
part, will be filed with the SEC to reflect the disclosure of additional information with respect to the distribution of the securities
covered by this prospectus. In order to comply with the securities laws of certain states, if applicable, the securities sold under this
prospectus may only be sold through registered or licensed broker-dealers. In addition, in some states the securities may not be sold
unless they have been registered or qualified for sale in the applicable state or an exemption from registration or qualification requirements
is available and is complied with.
The
distribution of securities may be effected from time to time in one or more transactions, including block transactions and transactions
on the Nasdaq Capital Market or any other organized market where the securities may be traded. The securities may be sold at a fixed
price or prices, which may be changed, or at market prices prevailing at the time of sale, at prices relating to the prevailing market
prices or at negotiated prices. The consideration may be cash, or another form negotiated by the parties. Agents, underwriters or broker-dealers
may be paid compensation for offering and selling the securities. That compensation may be in the form of discounts, concessions or commissions
to be received from us or from the purchasers of the securities. Any dealers and agents participating in the distribution of the securities
may be deemed to be underwriters, and compensation received by them on resale of the securities may be deemed to be underwriting discounts.
If any such dealers or agents were deemed to be underwriters, they may be subject to statutory liabilities under the Securities Act.
Agents
may from time to time solicit offers to purchase the securities. If required, we will name in the applicable prospectus supplement any
agent involved in the offer or sale of the securities and set forth any compensation payable to the agent. Unless otherwise indicated
in the prospectus supplement, any agent will be acting on a best-efforts basis for the period of its appointment. Any agent selling the
securities covered by this prospectus may be deemed to be an underwriter, as that term is defined in the Securities Act, of the securities.
To
the extent that we make sales to or through one or more underwriters or agents in at-the-market offerings, we will do so pursuant to
the terms of a distribution agreement between us and the underwriters or agents. If we engage in at-the-market sales pursuant to a distribution
agreement, we will sell any of our listed securities to or through one or more underwriters or agents, which may act on an agency basis
or on a principal basis. During the term of any such agreement, we may sell any of our listed securities on a daily basis in exchange
transactions or otherwise as we agree with the underwriters or agents. The distribution agreement will provide that any of our listed
securities which are sold will be sold at prices related to the then prevailing market prices for our listed securities. Therefore, exact
figures regarding proceeds that will be raised or commissions to be paid cannot be determined at this time and will be described in a
prospectus supplement. Pursuant to the terms of the distribution agreement, we also may agree to sell, and the relevant underwriters
or agents may agree to solicit offers to purchase, blocks of our listed securities. The terms of each such distribution agreement will
be set forth in more detail in a prospectus supplement to this prospectus.
If
underwriters are used in a sale, securities will be acquired by the underwriters for their own account and may be resold from time to
time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined
at the time of sale, or under delayed delivery contracts or other contractual commitments. Securities may be offered to the public either
through underwriting syndicates represented by one or more managing underwriters or directly by one or more firms acting as underwriters.
If an underwriter or underwriters are used in the sale of securities, an underwriting agreement will be executed with the underwriter
or underwriters, as well as any other underwriter or underwriters, with respect to a particular underwritten offering of securities,
and will set forth the terms of the transactions, including compensation of the underwriters and dealers and the public offering price,
if applicable. The prospectus and prospectus supplement will be used by the underwriters to resell the securities.
If
a dealer is used in the sale of the securities, we or an underwriter will sell the securities to the dealer, as principal. The dealer
may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale. To the extent required,
we will set forth in the prospectus supplement the name of the dealer and the terms of the transactions.
We
may directly solicit offers to purchase the securities and may make sales of securities directly to institutional investors or others.
These persons may be deemed to be underwriters within the meaning of the Securities Act with respect to any resale of the securities.
To the extent required, the prospectus supplement will describe the terms of any such sales, including the terms of any bidding or auction
process, if used.
Agents,
underwriters and dealers may be entitled under agreements which may be entered into with us to indemnification by us against specified
liabilities, including liabilities incurred under the Securities Act, or to contribution by us to payments they may be required to make
in respect of such liabilities. If required, the prospectus supplement will describe the terms and conditions of the indemnification
or contribution. Some of the agents, underwriters or dealers, or their affiliates may be customers of, engage in transactions with or
perform services for us or our subsidiaries.
Any
person participating in the distribution of securities registered under the registration statement that includes this prospectus will
be subject to applicable provisions of the Exchange Act and the applicable SEC rules and regulations, including, among others, Regulation
M, which may limit the timing of purchases and sales of any of our securities by that person. Furthermore, Regulation M may restrict
the ability of any person engaged in the distribution of our securities to engage in market-making activities with respect to our securities.
These restrictions may affect the marketability of our securities and the ability of any person or entity to engage in market-making
activities with respect to our securities.
Certain
persons participating in an offering may engage in over-allotment, stabilizing transactions, short-covering transactions, penalty bids
and other transactions that stabilize, maintain or otherwise affect the price of the offered securities. These activities may maintain
the price of the offered securities at levels above those that might otherwise prevail in the open market, including by entering stabilizing
bids, effecting syndicate covering transactions or imposing penalty bids, each of which is described below:
|
● |
a
stabilizing bid means the placing of any bid, or the effecting of any purchase, for the purpose of pegging, fixing or maintaining
the price of a security. |
|
|
|
|
● |
a
syndicate covering transaction means the placing of any bid on behalf of the underwriting syndicate or the effecting of any purchase
to reduce a short position created in connection with the offering. |
|
|
|
|
● |
a
penalty bid means an arrangement that permits the managing underwriter to reclaim a selling concession from a syndicate member in
connection with the offering when offered securities originally sold by the syndicate member are purchased in syndicate covering
transactions. |
These
transactions may be effected on an exchange or automated quotation system, if the securities are listed on that exchange or admitted
for trading on that automated quotation system, or in the over-the-counter market or otherwise.
If
so indicated in the applicable prospectus supplement, we will authorize agents, underwriters or dealers to solicit offers from certain
types of institutions to purchase offered securities from us at the public offering price set forth in such prospectus supplement pursuant
to delayed delivery contracts providing for payment and delivery on a specified date in the future. Such contracts will be subject only
to those conditions set forth in the prospectus supplement and the prospectus supplement will set forth the commission payable for solicitation
of such contracts.
In
addition, the securities may be issued upon conversion of or in exchange for debt securities or other securities.
Any
underwriters to whom offered securities are sold for public offering and sale may make a market in such offered securities, but such
underwriters will not be obligated to do so and may discontinue any market making at any time without notice. The offered securities
may or may not be listed on a national securities exchange. No assurance can be given that there will be a market for the offered securities.
Any
securities that qualify for sale pursuant to Rule 144 or Regulation S under the Securities Act, may be sold under Rule 144 or Regulation
S rather than pursuant to this prospectus.
In
connection with offerings made through underwriters or agents, we may enter into agreements with such underwriters or agents pursuant
to which we receive our outstanding securities in consideration for the securities being offered to the public for cash. In connection
with these arrangements, the underwriters or agents may also sell securities covered by this prospectus to hedge their positions in these
outstanding securities, including in short sale transactions. If so, the underwriters or agents may use the securities received from
us under these arrangements to close out any related open borrowings of securities.
We
may enter into derivative transactions with third parties or sell securities not covered by this prospectus to third parties in privately
negotiated transactions. If the applicable prospectus supplement indicates, in connection with those derivatives, such third parties
(or affiliates of such third parties) may sell securities covered by this prospectus and the applicable prospectus supplement, including
in short sale transactions. If so, such third parties (or affiliates of such third parties) may use securities pledged by us or borrowed
from us or others to settle those sales or to close out any related open borrowings of shares and may use securities received from us
in settlement of those derivatives to close out any related open borrowings of shares. The third parties (or affiliates of such third
parties) in such sale transactions will be underwriters and will be identified in the applicable prospectus supplement (or a post-effective
amendment).
We
may loan or pledge securities to a financial institution or other third party that in turn may sell the securities using this prospectus.
Such financial institution or third party may transfer its short position to investors in our securities or in connection with a simultaneous
offering of other securities offered by this prospectus or in connection with a simultaneous offering of other securities offered by
this prospectus.
TAXATION
The
material Australian and U.S. federal income tax consequences relating to the purchase, ownership and disposition of any of the securities
offered by this prospectus will be set forth in the prospectus supplement offering those securities.
EXPENSES
The
following is a statement of expenses in connection with the distribution of the securities registered. All amounts shown are estimates
except the SEC registration fee and FINRA fee. The estimates do not include expenses related to offerings of particular securities. Each
prospectus supplement describing an offering of securities will reflect the estimated expenses related to the offering of securities
under that prospectus supplement.
U.S. Securities and Exchange Commission registration fee | |
$ | 11,070 | |
Legal fees and expenses | |
| 60,000 | |
FINRA fee | |
| 11,750 | |
Accounting fees and expenses | |
| 20,000 | |
Printing expenses | |
| 2.000 | |
Depositary fees and expenses | |
| 5,000 | |
Other miscellaneous fees and expenses | |
| 2,000 | |
Total | |
$ | 111,820 | |
LEGAL
MATTERS
Certain
legal matters with respect to Australian law with respect to the validity of the offered securities will be passed upon for the Company
by K&L Gates, Melbourne, Victoria. Sichenzia Ross Ference Carmel LLP, New York, NewYork, will be passing upon matters of United States
law for us with respect to securities offered by this prospectus and any accompanying prospectus supplement.
EXPERTS
The
consolidated financial statements incorporated by reference in this prospectus and elsewhere in this Registration Statement have been
so incorporated by reference in reliance upon the report of Grant Thornton Audit Pty Ltd, an independent registered public accountants,
upon the authority of said firm as experts in auditing and accounting.
ENFORCEMENT
OF CIVIL LIABILITIES
We
are a public limited company incorporated under the laws of Australia. All of our directors and executive officers are non-residents
of the United States, and all or substantially all of the assets of such persons are located outside the United States. As a result,
it may not be possible for you to:
|
● |
effect
service of process within the United States upon any of our directors and executive officers or on us; |
|
|
|
|
● |
enforce
in U.S. courts judgments obtained against any of our directors and executive officers or us in the U.S. courts in any action, including
actions under the civil liability provisions of U.S. securities laws; |
|
|
|
|
● |
enforce
in U.S. courts judgments obtained against any of our directors and executive officers or us in courts of jurisdictions outside the
United States in any action, including actions under the civil liability provisions of U.S. securities laws; or |
|
|
|
|
● |
to
bring an original action in an Australian court to enforce liabilities against any of our directors and executive officers or us
based upon U.S. securities laws. |
You
may also have difficulties enforcing in courts outside the United States judgments obtained in the U.S. courts against any of our directors
and executive officers or us, including actions under the civil liability provisions of the U.S. securities laws.
INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE
The
SEC allows us to “incorporate by reference” information into this prospectus, which means that we can disclose important
information to you by referring you to other documents which we have filed or will file with the SEC. The information incorporated by
reference is considered a part of this prospectus and should be read carefully. Certain information in this prospectus supersedes information
incorporated by reference that we filed with the SEC prior to the date of this prospectus. Certain information that we file later with
the SEC will automatically update and supersede the information in this prospectus. Any statement so modified or superseded shall not
be deemed, except as so modified or superseded, to constitute a part of this prospectus.
We
incorporate by reference into this prospectus and the registration statement of which it is a part the following documents, including
any amendments to such filings:
|
● |
our
annual report on Form 20-F for the fiscal year ended June 30, 2023, filed with the SEC on August 30, 2023; |
|
|
|
|
● |
our
Form 6-Ks furnished with the SEC on July 28, 2023; August 30, 2023; August 31, 2023; September 11, 2023; September 27, 2023, October 30, 2023; November 21, 2023; November 24, 2023; December 1, 2023; December 6, 2023; December 7, 2023; December 12, 2023 and December 19, 2023; |
|
● |
the
description of our securities contained in Exhibit 2.2 to our Annual Report on Form 20-F for the year ended June 30, 2023 filed with
the SEC on August 30, 2023, and any amendment or report filed for the purpose of further updating that description. |
We
are also incorporating by reference all subsequent Annual Reports on Form 20-F that we file with the SEC and certain reports on Form
6-K that we furnish to the SEC after the date of this prospectus (if they state that they are incorporated by reference into this prospectus)
prior to the termination of this offering. In all cases, you should rely on the later information over different information included
in this prospectus or any accompanying prospectus supplement.
Unless
expressly incorporated by reference, nothing in this prospectus shall be deemed to incorporate by reference information furnished to,
but not filed with, the SEC. Copies of all documents incorporated by reference in this prospectus, other than exhibits to those documents
unless such exhibits are specifically incorporated by reference in this prospectus, will be provided at no cost to each person, including
any beneficial owner, who receives a copy of this prospectus on the written or oral request of that person made to:
Simon
Morriss
60-66
Hanover Street
Fitzroy,
Victoria, 3065, Australia
Tel:
011613-8412-7000
You
may also access these documents on our website, www.genetype.com.The information contained on, or that can be accessed through, our website
is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.
WHERE
YOU CAN FIND MORE INFORMATION
We
have filed with the SEC a registration statement (including exhibits to the registration statement) on Form F-3 under the Securities
Act. This prospectus, which is part of the registration statement, does not contain all of the information set forth in the registration
statement and the exhibits and schedules to the registration statement. For further information, we refer you to the registration statement
and the exhibits and schedules filed as part of the registration statement. If a document has been filed as an exhibit to the registration
statement, we refer you to the copy of the document that has been filed. Each statement in this prospectus relating to a document filed
as an exhibit is qualified in all respects by the filed exhibit.
We
are subject to the informational requirements of the Exchange Act. Our annual report on Form 20-F for the year ending June 30, 2023 has
been filed with the SEC. The company has also filed reports with the SEC on Form 6-K. The SEC maintains an Internet website that contains
reports and other information about issuers, like us, that file electronically with the SEC. The address of that website is www.sec.gov.
As
a foreign private issuer, we are exempt under the Exchange Act from, among other things, the rules prescribing the furnishing and content
of proxy statements, and our executive officers, directors and principal shareholders are exempt from the reporting and short-swing profit
recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file periodic
reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the
Exchange Act.
$75,000,000
American
Depositary Shares Representing Ordinary Shares
Preference Shares
Warrants
Units
GENETIC
TECHNOLOGIES LIMITED
PROSPECTUS
,
2023
PART
II
INFORMATION
NOT REQUIRED IN PROSPECTUS
Item
8. Indemnification Of Directors And Officers
Except
as hereinafter set forth, there is no provision of the Company’s Constitution or any contract, arrangement or statute under which
any director or officer of the Company is insured or indemnified in any manner against liability which he may incur in his capacity as
such.
Rule
35 of the Company’s Constitution provides:
To
the extent permitted by law:
(a)
the company must indemnify each Director and Secretary and each former Director and Secretary, and may indemnify any other officer or
former officer of the Company (as that term is defined in section 9 of the Corporations Act 2001 (Cth)), against any liability (other
than legal costs) incurred in acting as a Director, Secretary, or, where applicable, other officer of the company other than:
(i)
a liability owed to the company or a related body corporate;
(ii)
a liability for a pecuniary penalty order under section 1317G or a compensation order under section 1317H of the Corporations Act 2001
(Cth); or
(iii)
a liability that did not arise out of conduct in good faith;
(b)
the company must indemnify each Director and Secretary and each former Director and Secretary who is or was, at the request of the company,
serving as a director or secretary of another company against any liability (other than legal costs) incurred in acting as a director
or secretary of the other company other than:
(i)
a liability owed to the other company or a Related Body Corporate;
(ii)
a liability for a pecuniary penalty order under section 1317G or a compensation order under section 1317H of the Corporations Act 2001
(Cth); or
(iii)
a liability that did not arise out of conduct in good faith;
(c)
the company must indemnify each Director and Secretary, and each former Director and Secretary, and may indemnify any other officer or
former officer, for costs and expenses incurred by a Director, Secretary or, where applicable, other officer of the company, in defending
an action for a liability incurred in acting as a Director, Secretary or, where applicable, other officer of the company, except for
legal costs incurred:
(i)
in defending or resisting any proceedings, whether civil or criminal, in which the Director, Secretary or, where applicable, other officer
of the company, is found to have a liability for which they could not be indemnified under clause (a) above;
(ii)
in defending or resisting criminal proceedings in which the Director, Secretary or, where applicable, other officer of the company, is
found guilty;
(iii)
in defending or resisting proceedings brought by the ASIC or by a liquidator for a court order if the grounds for making the order are
found by the court to have been established, except for costs incurred in responding to actions taken by the ASIC or a liquidator as
part of an investigation before commencing proceedings for the court order; or
(iv)
in connection with proceedings for relief to the Director, Secretary or, where applicable, other officer of the company, under the Act
in which the relief is denied by the court;
(d)
the company must indemnify each Director and Secretary and each former Director and Secretary who is or was, at the request of the company,
serving as a director or secretary of another company for costs and expenses incurred by the Director or Secretary in defending an action
for a liability incurred in acting as a director or secretary of the other company, except for legal costs incurred:
(i)
in defending or resisting any proceedings, whether civil or criminal, in which the Director or Secretary is found to have a liability
for which they could not be indemnified under clause (b) above;
(ii)
in defending or resisting criminal proceedings in which the Director or Secretary is found guilty;
(iii)
in defending or resisting proceedings brought by the ASIC or by a liquidator for a court order if the grounds for making the order are
found by the court to have been established, except for costs incurred in responding to actions taken by the ASIC or a liquidator as
part of an investigation before commencing proceedings for the court order; or
(iv)
in connection with proceedings for relief to the Director or Secretary under the Corporations Act 2001 (Cth) in which the relief is denied
by the court; and
(e)
the company must make a payment, or agree to make a payment, whether by way of advance, loan or otherwise, for any reasonable legal costs
incurred by a Director, Secretary or, where applicable, other officer of the company, on the condition that the Director, Secretary or,
where applicable, other officer of the company, must repay the amount paid by the company to the extent that the company is found to
be not able to indemnify the Director, Secretary or, where applicable, other officer of the company, for those legal costs.
To
the extent permitted by law and to the extent the company is able to obtain it, the company must maintain and pay all premiums for an
insurance policy insuring each Director, Secretary or other officer of the company or of a subsidiary of the company against liability
incurred in that capacity for the period of the person’s engagement and for a 7 year period thereafter (and if legal action is
commenced prior to the expiry of that date then until the final determination of that action) in an amount which is not less than the
amount provided to Directors during that period, or if no such policy is in existence then on the terms and conditions that are in substance
no less favorable to the person than those of any insurance policy that last covered the person.
This
Rule 35 does not limit any right the person otherwise has.
In
this Rule 35, an officer means a director or secretary of the corporation, or a person who makes, or participates in making, decisions
that affect the whole, or a substantial part, of the business of the corporation, or who has the capacity to affect significantly the
corporation’s financial standing.
The
Company maintains liability insurance policies insuring the Company’s directors and officers against certain liabilities that they
may incur in such capacities.
Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons
of the Company pursuant to the charter provision, by-law, contract, arrangements, statute or otherwise, we have been informed that, in
the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act
and is, therefore, unenforceable.
Item
9. Exhibits
See
the Exhibit Index included herewith which is incorporated herein by reference.
Item
10. Undertakings
The
undersigned registrant hereby undertakes:
(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
(i)
to include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii)
to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Securities and Exchange Commission (the “Commission”) pursuant
to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate
offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and
(iii)
to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or
any material change to such information in the registration statement;
provided,
however, that paragraphs (1)(i), (1)(ii) and (1)(iii) do not apply if the registration statement is on Form S-3 or Form F-3 and the
information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished
to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in
the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.
(2)
That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be
a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof.
(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.
(4)
That, for the purpose of determining liability under the Securities Act to any purchaser:
(i)
Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the
date the filed prospectus was deemed part of and included in the registration statement; and
(ii)
Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on
Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information
required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the
earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of
securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and
any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement
relating to the securities in the registration statement to which the prospectus relates, and the offering of such securities at
that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration
statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by
reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a
time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement
or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date;
or
(5)
That, for the purpose of determining liability of the undersigned registrant under the Securities Act to any purchaser in the initial
distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant
pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities
are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to
the purchaser and will be considered to offer or sell such securities to such purchaser:
(i)
Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule
424;
(ii)
Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by
the undersigned registrant;
(iii)
The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
or its securities provided by or on behalf of the undersigned registrant; and
(iv)
Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
(b)
That, for purposes of determining any liability under the Securities Act each filing of the registrant’s annual report pursuant
to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant
to Section 15(d) of the Exchange Act), that is incorporated by reference in the registration statement shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial
bona fide offering thereof.
(c)
The undersigned registrant hereby undertakes to supplement the prospectus, after the expiration of the subscription period, to set forth
the results of the subscription offer, the transactions by the underwriters during the subscription period, the amount of unsubscribed
securities to be purchased by the underwriters, and the terms of any subsequent reoffering thereof. If any public offering by the underwriters
is to be made on terms differing from those set forth on the cover page of the prospectus, a post-effective amendment will be filed to
set forth the terms of such offering.
(d)
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons
of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless
in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue.
(e)
The undersigned Registrant hereby undertakes that:
i.
For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed
as part of this Registration Statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant
to Rule 424(b)(1) or (4) or 497(h) under the Securities Act of 1933 shall be deemed to be part of this Registration Statement as of the
time it was declared effective.
ii.
For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of
prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.
(f)
The undersigned Registrant hereby undertakes to file an application for the purpose of determining the eligibility of the trustee to
act under subsection (a) of Section 310 of the Trust Indenture Act in accordance with the rules and regulations prescribed by the SEC
under Section 305(b)(2) of the Trust Indenture Act.
EXHIBIT
INDEX
Exhibit
No. |
|
Exhibit
Description |
1.1** |
|
Form
of Underwriting Agreement |
3.1 |
|
Constitution (incorporated by reference to Exhibit 1.1 of the Company’s Registration Statement on Form 20-F filed with the SEC on December 21, 2010) |
4.1 |
|
Deposit Agreement, dated as of January 14, 2002, by and among Genetic Technologies Limited, The Bank of New York Mellon, as Depositary, and the Owners and Holders of American Depositary Receipts (incorporated by reference to Exhibit 1 of the Company’s Registration Statement on Form F-6 relating to the ADSs filed with the SEC on September 12, 2012) |
4.2 |
|
Form of American Depositary Receipt (incorporated by reference to Rule 424(b)(3) filing (File No. 333-183861), filed with the SEC on December 7, 2023) |
4.3** |
|
Form
of ADS Warrant Agent Agreement |
4.4** |
|
Form
of Certificate of Designation of Preference Shares |
4.5** |
|
Form
of Global Warrant to Purchase ADSs (included in Exhibit 4.3) |
4.6** |
|
Form
of Unit Agreement (including form of Unit Certificate) |
5.1* |
|
Opinion of K&L Gates, Australian counsel to Company |
23.1* |
|
Consent of Grant Thornton |
23.2* |
|
Consent of K&L Gates, Australian counsel to Company (included in Exhibit 5.1) |
24.1 |
|
Power of Attorney (included on signature page to this registration statement) |
107* |
|
Filing fee table |
*
Filed herewith.
**
To be filed, if applicable, by amendment, or as an exhibit to a report on Form 6-K and incorporated herein by reference.
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form F-3 and has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in Victoria, Australia, on December 20, 2023.
|
GENETIC
TECHNOLOGIES LIMITED |
|
|
|
|
By: |
/s/
Simon Morriss |
|
|
Simon
Morriss |
|
|
Chief
Executive Officer |
POWER
OF ATTORNEY
Each
person whose signature appears below does hereby constitute and appoint Simon Morriss and Tony Di Pietro and each of them singly (with
full power to act alone), as his true and lawful attorneys-in-fact and agents, each with full power of substitution and re-substitution,
for him and in his name, place and stead, in any and all capacities, in connection with this registration statement, including to sign
and file in the name and on behalf of the undersigned as director or officer of the registrant, any and all amendments and supplements
(and any and all prospectus supplements, stickers and post-effective amendments) to this registration statement with all exhibits thereto,
and sign any registration statement for the same offering covered by this registration statement that is to be effective upon filing
pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and all post-effective amendments thereto and to file the same,
with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, and any applicable
securities exchange, securities self-regulatory body or other regulatory entity, granting unto said attorneys-in-fact and agents, and
each of them (with full power to act alone) full power and authority to do and perform each and every act and thing requisite and necessary
to be done in connection therewith and in and about the premises, as fully to all intents and purposes as he might or could do in person,
hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes may lawfully
do or cause to be done by virtue hereof.
Pursuant
to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and
on the dates indicated.
Signature |
|
Title |
|
Date |
|
|
|
|
|
/s/
Simon Morriss |
|
Chief
Executive Officer
(principal executive officer) |
|
December
20 2023 |
Simon
Morriss |
|
|
|
|
|
|
|
|
/s/
Tony Di Pietro |
|
Chief
Financial Officer |
|
December
20, 2023 |
Tony
Di Pietro |
|
(principal
financial and accounting officer) |
|
|
|
|
|
|
|
/s/
Dr. Lindsay Wakefield |
|
Director |
|
December
20, 2023 |
Dr.
Lindsay Wakefield |
|
|
|
|
|
|
|
|
|
/s/
Peter Rubinstein |
|
Director |
|
December
20, 2023 |
Peter
Rubinstein |
|
|
|
|
|
|
|
|
|
/s/
Nick Burrows |
|
Director |
|
December
20, 2023 |
Nick
Burrows |
|
|
|
|
|
|
|
|
|
/s/
Dr. Jerzy Muchnicki
|
|
Director |
|
December
20, 2023 |
Dr.
Jerzy Muchnicki |
|
|
|
|
SIGNATURE
OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES
Pursuant
to the requirement of the Securities Act, the duly authorized representative in the United States of Genetic Technologies Limited, has
signed this registration statement in the City of Newark, Delaware, on December 20, 2023.
|
By: |
/s/
DONALD J. PUGLISI |
|
Name: |
Donald
J. Puglisi |
|
Title: |
Managing
Director |
|
Authorized
Representative in the United States |
Exhibit
5.1
20
December 2023
The
Board of Directors
Genetic
Technologies Limited
60-66
Hanover Street
FITZROY
VIC 3065
|
Partner:
Andrew Gaffney
andrew.gaffney@klgates.com
T
+61 3 9640 4329
Our
ref: gaffnea:7377758.00047 |
Dear
Sirs
Form
F-3 Registration Statement
We
have acted as Australian legal counsel for Genetic Technologies Limited ACN 009 212 328, a company incorporated under the laws of the
Commonwealth of Australia (“Company”), in connection with its filing of a registration statement on Form F-3 (“Registration
Statement”) under the Securities Act of 1933 (USA) as amended (the “Securities Act”), with the U.S. Securities
and Exchange Commission (“SEC”).
The
Registration Statement relates to the proposed offer and sale by the Company from time to time, as set out in the prospectus contained
in the Registration Statement (the “Prospectus”) and as, we are instructed, will be set out in one or more supplements
to the Prospectus (each a “Prospectus Supplement”), of the Company’s ordinary shares without par value (“Shares”)
represented by American Depositary Shares (as evidenced by American Depositary Receipts, each representing 30 Shares) (“ADS”),
preference shares (“Preference Shares”), warrants (“Warrants”), or units (“Units”),
in such amounts as will have an aggregate offering price not exceeding US$75,000,000 (the Shares, Preference Shares, Warrants and Units
being referred to herein as the “Securities”).
The
Registration Statement (including the Prospectus) and the Prospectus Supplement are hereinafter referred to as the “Documents”.
This
opinion is given in relation to a proposed offering of the Securities under Rule 415 of the Securities Act.
Assumptions
in providing our opinion
As
to various questions of fact relevant to this opinion, we have relied on and assumed the accuracy of, without independent verification:
● |
an
online search of the Company on the Australian Securities and Investments Commission (“ASIC”) records on December
20, 2023 (“ASIC search”); and |
● |
the
Company’s Constitution (a copy of which was provided to us by the Company). |
Level
25 South Tower 525 Collins Street Melbourne VIC 3000 Australia
GPO
Box 4388 Melbourne VIC 3001 DX 405 Melbourne
T
+61 3 9205 2000 F +61 3 9205 2055 klgates.com
For
the purpose of the opinions set out below, we have also assumed, with your agreement and without independent investigation or verification,
that:
|
(a) |
all
signatures are genuine and all documents, instruments and certificates submitted to us as originals are authentic and conform exactly
with the authentic originals of all documents, instruments and certificates submitted to us as copies or forms or originals; |
|
(b) |
each
party to each document has all the requisite power and authority (corporate and otherwise) to execute and deliver and perform its
obligations there under; |
|
(c) |
all
matters of internal management required by the constitution of each of the parties to the relevant documents have been duly attended
to (including, without limitation, the holding of properly constituted meetings of the boards of directors of each of those parties
and the passing at those meetings of appropriate resolutions); |
|
(d) |
any
documents which purport to be governed by the law of any jurisdiction other than the federal and state laws of the Commonwealth of
Australia are legal, valid and binding obligations on all of the parties thereto and under the applicable law and that none of the
execution, delivery or performance of any document by any party thereto violates or contravenes or is rendered invalid, not binding
or unenforceable under any applicable law under any jurisdiction other than the federal and state laws of the Commonwealth of Australia; |
|
(e) |
the
Company will not engage in fraudulent or unconscionable conduct or conduct which is misleading or deceptive or which is likely to
mislead or deceive in relation to the issuance or sale of the Securities; |
|
(f) |
there
is no bad faith, fraud, undue influence, coercion or duress or similar conduct on the part of the Company in relation to the issuance
or sale of Shares or ADS under the Registration Statement; |
|
(g) |
all
information provided to us by or on behalf of officers of the Company was true, correct and complete when provided and remains so
at the date of this letter, containing all information required, without us making any separate enquiry or investigation other than
viewing the ASIC search, in order for us to provide this opinion; |
|
(h) |
the
issuance, sale, number or amount, as the case may be, and terms of the Securities, or any combination thereof, to be offered from
time to time under the Documents will be duly authorised by the Company’s Board of Directors and the Company’s shareholders,
in accordance with the Constitution of the Company, the listing rules of the ASX Limited (“ASX Listing Rules”)
and applicable Australian law (each a “Corporate Action”), although not all required Corporate Actions in relation
to issuance of the Securities have been taken as at the date of this opinion; |
|
(i) |
no
party has contravened or will contravene any provision of the Australian Corporations Act 2001 (including Chapters 2E, 2J, 6 or generally
sections 1041H or 1043A) (“Corporations Act”) by entering into a Document or giving effect to any transaction
in connection with a Document or undertaking or being involved in a transaction related to or connected with the Documents; |
|
(j) |
the
Company will at all times duly comply with all its obligations under the Corporations Act, the ASX Listing Rules and otherwise required
by law; |
|
(k) |
the
Company is and will be able to pay its debts as and when they fall due and is otherwise solvent as at the time the Securities are
issued or sold; and |
|
(l) |
the
ASIC search we have examined is accurate and that the information disclosed by the search conducted by us is true and complete and
that such information has not since then been altered and that such search did not fail to disclose any information which had been
delivered for registration or filing against the Company’s records but which did not appear on the public records at the date
of our search. |
Opinion
Subject
to (i) the Registration Statement (including the Prospectus), as amended (including all necessary post-effective amendments), becoming
effective under the Securities Act (and on the assumption it will remain effective at the time of issuance of any Securities thereunder),
(ii) an appropriate Prospectus Supplement with respect to the offering of the Securities (if applicable) being prepared, delivered and
timely filed in compliance with the Securities Act and the applicable rules and regulations thereunder, (iii) the Securities to be sold
pursuant to the Prospectus Supplement being duly authorized, executed and delivered by each of the Board of Directors, the Company’s
shareholders and, where applicable, all other parties thereto (and will be in full force and effect at all times at which the Securities
are offered or sold by the Company), (iv) the Board of Directors, the Company shareholders and appropriate officers of the Company have
taken all necessary Corporate Action to approve the issuance of the Securities on the definitive terms established thereunder, (v) the
agreed upon consideration being received for the issue of the Securities and related matters, and (vi) the terms of the issuance and
sale of the Securities being in conformity with the Company’s Constitution, the Corporations Act and the ASX Listing Rules so as
not to violate any applicable law or result in a default under or breach of any agreement or instrument binding upon the Company and
so as to comply with any requirement or restriction imposed by any court or governmental body having jurisdiction over the Company in
our opinion:
1. |
the
Shares will be legally issued, fully paid and non-assessable; |
2. |
the
Preference Shares will be legal issued, fully paid and non-assessable; |
3. |
in
the case of any Warrants, pursuant to a warrant agreement or agreements, approved by, or on behalf of, the Company’s Board
of Directors and duly authorized, executed and delivered by the Company and between the Company and a warrant agent, the Warrants
will be valid and binding obligations of the Company, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium
and similar laws of general applicability relating to or affecting creditors’ rights and to general equity principles; and |
4. |
upon
the exercise of any Warrants and the Company receiving any additional consideration which is payable upon the exercise of the Warrants,
the Shares issuable upon the exercise of the Warrants will be legally issued, fully paid and non-assessable. |
This
opinion is limited to the federal and state laws of the Commonwealth of Australia and no opinion or representation is given in respect
of the application of any foreign laws to the issue or transfer of the securities or the contents or generally the compliance of the
Registration Statement, the Prospectus Supplement or any other matters under any applicable US laws or regulations.
Applicability
This
opinion is given as at the date of this letter and we undertake no obligation to investigate or review any matters arising after the
date of this opinion nor to advise you of any changes or events (including but not limited to any subsequently enacted, published or
reported laws, regulations or individual decisions) that may occur or come to our attention after the date of this opinion which may
affect our opinion.
This
opinion letter is limited to the matters stated herein, and no opinion is implied or may be inferred beyond the matters expressly stated.
This opinion may not be relied upon by any person or entity other than you, quoted in whole or in part or otherwise referred to in any
report or document or relied upon for any purpose other than in connection with the offer, issuance and sale of Securities under the
Registration Statement or any Prospectus Supplement from time to time without our prior written approval.
We
consent to incorporation by reference of this opinion in the Registration Statement and to the reference of this firm under the caption
“Legal Matters” therein, and we consent to the filing of this opinion as an exhibit 5.1 to the Company’s Registration
Statement.
Yours
faithfully
Andrew
Gaffney
Partner
K&L
Gates
Exhibit
23.1
CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We
have issued our report dated August 30, 2023 with respect to the consolidated financial statements of Genetic Technologies Limited and
subsidiaries included in the Annual Report on Form 20-F for the year ended June 30, 2023, which are incorporated by reference in this
registration statement. We consent to the incorporation by reference of the aforementioned report in this Registration Statement, and
to the use of our name as it appears under the caption “Experts”.
/s/
GRANT THORNTON AUDIT PTY LTD
Melbourne,
Australia
December
20, 2023
Exhibit
107
Calculation
of Filing Fee Tables
Form
F-3
(Form
Type)
Genetic
Technologies Limited
(Exact
Name of Registrant as Specified in its Charter)
Table
1: Newly Registered Securities and Carry Forward Securities
| |
Security Type | |
Security Class Title | |
Fee
Calculation or Carry Forward Rule | | |
Amount
Registered (1) | | |
Proposed
Maximum Offering Price Per
Unit (2) | | |
Maximum
Aggregate Offering Price (3) | | |
Fee Rate | | |
Amount
of Registration Fee | |
Fees to Be Paid | |
Equity | |
Ordinary shares (5) | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Fees to Be Paid | |
Equity | |
Preference
shares | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Fees to Be Paid | |
Other | |
Warrants | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Fees to Be Paid | |
Other | |
Units | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Fees to Be Paid | |
Unallocated (Universal) Shelf | |
Unallocated (Universal) Shelf | |
| 457(o) | | |
| | (2) | |
| | (3) | |
$ | 75,000,000 | | |
| 0.0001476 | | |
$ | 11,070.00 | (4) |
| |
| |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| |
Total Offering Amounts | | |
| | | |
| | | |
| | | |
$ | 11,070.00 | |
| |
Total Fees Previously Paid | | |
| | | |
| | | |
| | | |
| — | |
| |
Total Fee Offsets | | |
| | | |
| | | |
| | | |
$ | — | |
| |
Net Fee Due | | |
| | | |
| | | |
| | | |
$ | 11,070.00 | |
(1) There are being registered under this registration statement such indeterminate number of ordinary shares, preference shares, warrants and units, as may be sold by the registrant from time to time, which collectively shall have an aggregate initial offering price not to exceed $75,000,000 or, if any securities are issued for consideration denominated in a foreign currency, such amount as shall result in an aggregate initial offering price equivalent to a maximum of $75,000,000. The securities registered hereunder also include such indeterminate number of ordinary shares as may be issued upon conversion, exercise or exchange of warrants that provide for such conversion into, exercise for or exchange into ordinary shares. In addition, pursuant to Rule 416 under the Securities Act of 1933, as amended, or the Securities Act, the ordinary shares being registered hereunder include such indeterminate number of ordinary shares as may be issuable with respect to the shares being registered hereunder as a result of stock splits, stock dividends, or similar transactions.
(2) Not specified as to each class of securities to be registered pursuant to General Instruction II.C. of Form F-3.
(3) The proposed maximum offering price per unit of each class of securities will be determined from time to time by the Registrant in connection with the issuance by the Registrant of the securities registered hereunder and is not specified as to each class of security pursuant to General Instruction II.D. of Form F-3 under the Securities Act of 1933, as amended (the “Securities Act”).
(4) The registration fee has been calculated pursuant to Rule 457(o) under the Securities Act on the basis of the maximum aggregate offering price of the securities listed.
(5) Ordinary shares may be in the form of American Depositary Shares. American Depositary Shares issuable on deposit of the ordinary shares registered hereby have been registered under a separate registration statement on Form F-6 (File No. 333-183861). Each American Depositary Share represents the right to receive 30 ordinary shares.
Genetic Technologies (NASDAQ:GENE)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Genetic Technologies (NASDAQ:GENE)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024